#### Title: Identification of a serum proteomic biomarker panel using 1 diagnosis specific ensemble learning and symptoms for early 2 pancreatic cancer detection 3

4

#### 5 Authors:

Alexander Ney<sup>1,\*</sup>, Nuno R. Nené<sup>2,3,4\*</sup>, Eva Sedlak<sup>2</sup>, Pilar Acedo<sup>1</sup>, Oleg Blyuss<sup>2,5,6</sup>, 6 Harry J. Whitwell<sup>2,7,8</sup>, Eithne Costello<sup>9</sup>, Aleksandra Gentry-Maharaj<sup>2,10</sup>, Norman R. 7 Williams<sup>11</sup>, Usha Menon<sup>10</sup>, Giuseppe K. Fusai<sup>12</sup>, Alexey Zaikin<sup>2,13,14</sup>, Stephen P. 8 9 Pereira<sup>1,\*</sup>.

10

#### 11 Affiliations:

12

- 13 <sup>1</sup> Institute for Liver and Digestive Health, University College London, Upper 3<sup>rd</sup> Floor, 14 Royal Free Campus, Rowland Hill Street, London NW3 2PF, United Kingdom
- 15
- <sup>2</sup> Department of Women's Cancer, EGA Institute for Women's Health, University 16 17 College London, 84-86 Chenies Mews, London, WC1E 6HU, United Kingdom 18
- 19 <sup>3</sup> Cancer Institute, University College London, 72 Huntley St, London, WC1E 6DD, 20 United Kingdom.
- 21
- 4 22 of University Department Statistical Science. College London 23 1-19 Torrington Place, London, WC1E 6BT, United Kingdom 24
- 25 <sup>5</sup> Wolfson Institute of Population Health, Queen Mary University of London, Charterhouse Square, EC1M 6BQ, London, United Kingdom 26 27
- 28 <sup>6</sup> Department of Pediatrics and Pediatric Infectious Diseases, Institute of Child's 29 Health, Sechenov First Moscow State Medical University (Sechenov University), 30 Moscow, Russia
- 31 <sup>7</sup> National Phenome Centre and Imperial Clinical Phenotyping Centre, Department of 32 Metabolism, Digestion and Reproduction, IRDB, Building Imperial College London, 33 W12 ONN, United Kingdom
- 34 <sup>8</sup> Section of Bioanalytical Chemistry, Division of Systems Medicine, Department of 35 Metabolism, Digestion and Reproduction, Sir Alexander Fleming Building, Imperial 36 College London, SW7 2AZ, United Kingdom
- 37
- 38 9 Department of Molecular and Clinical Cancer Medicine. University of 39 Liverpool, Liverpool, United Kingdom
- 40
- 41 <sup>10</sup> MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, 90 High Holborn, 2nd Floor, London, WC1V 6LJ, United 42 43 Kingdom
- 44

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 45 <sup>11</sup> Division of Surgery & Interventional Science, University College London, London, 46 United Kingdom
- 47
- 48 <sup>12</sup> HPB & Liver Transplant Unit, Royal Free London, London NW3 2QG, United 49 Kingdom
- 50 51 <sup>13</sup> Institute for Cognitive Neuroscience, University Higher School of Economics, 52 Moscow, Russia
- 53
- <sup>14</sup> Department of Mathematics, University College London, London WC1H 0AY, United 54 55 Kingdom
- 56
- 57 \* These authors contributed equally to the work
- 58
- 59 To whom correspondence should be addressed:
- 60 Dr Alexander Ney (Email: alexander.ney.15@ucl.ac.uk)
- 61 Dr Nuno Rocha Nené (Email: nuno.nene.10@ucl.ac.uk)
- 62 Prof Stephen Pereira (Email: stephen.pereira@ucl.ac.uk)
- 63 64

#### 65 Abstract

66 67 BACKGROUND: The grim (<10% 5-year) survival rates for pancreatic ductal adenocarcinoma (PDAC) 68 are attributed to its complex intrinsic biology and most often late-stage detection. The overlap of 69 symptoms with benign gastrointestinal conditions in early stage further complicates timely detection. 70 The suboptimal diagnostic performance of carbohydrate antigen (CA) 19-9 and elevation in benign 71 hyperbilirubinaemia undermine its reliability, leaving a notable absence of accurate diagnostic 72 biomarkers. Using a selected patient cohort with benign pancreatic and biliary tract conditions we aimed 73 to develop a biomarker signature capable of distinguishing patients with non-specific yet concerning 74 clinical presentations, from those with PDAC.

75

76 METHODS: 539 patient serum samples collected under the Accelerated Diagnosis of neuro Endocrine 77 and Pancreatic TumourS (ADEPTS) study (benign disease controls and PDACs) and the UK 78 Collaborative Trial of Ovarian Cancer Screening (UKCTOCS, healthy controls) were screened using 79 the Olink Oncology II panel, supplemented with five in-house markers. 16 specialized base-learner

80 classifiers were stacked to select and enhance biomarker performances and robustness in blinded 81 samples. Each base-learner was constructed through cross-validation and recursive feature elimination 82 in a discovery set comprising approximately two thirds of the ADEPTS and UKCTOCS samples and 83 contrasted specific diagnosis with PDAC.

84

85 RESULTS: The signature which was developed using diagnosis-specific ensemble learning 86 demonstrated predictive capabilities outperforming CA19-9 and individual biomarkers in both discovery 87 and validation sets. An AUC of 0.98 (95% CI 0.98 - 0.99) and sensitivity of 0.99 (95% CI 0.98 - 1) at 88 90% specificity was achieved with the ensemble method, which was significantly larger than the AUC 89 of 0.79 (95% CI 0.66 - 0.91) and sensitivity 0.67 (95% CI 0.50 - 0.83), also at 90% specificity, for CA19-90 9, in the discovery set (p=0.0016 and p=0.00050, respectively). During ensemble signature validation, 91 an AUC of 0.95 (95% CI 0.91 - 0.99), sensitivity 0.86 (95% CI 0.68 - 1), was attained compared to an 92 AUC of 0.80 (95% CI 0.66 - 0.93), sensitivity 0.65 (95% CI 0.48 - 0.56) at 90% specificity for CA19-9 93 alone (p=0.0082 and p=0.024, respectively). When validated only on the benign disease controls and 94 PDACs collected from ADEPTS, the diagnostic-specific signature achieved an AUC of 0.96 (95% CI 95 0.92 - 0.99), sensitivity 0.82 (95% CI 0.64 - 0.95) at 90% specificity, which was still significantly higher 96 than the performance for CA19-9 taken as a single predictor, AUC of 0.79 (95% CI 0.64-0.93) and 97 sensitivity of 0.18 (95% CI 0.03 – 0.69) (p= 0.013 and p=0.0055, respectively).

98 CONCLUSION: Our ensemble modelling technique outperformed CA19-9, individual biomarkers and
 99 prevailing algorithms in distinguishing patients with non-specific but concerning symptoms from those
 100 with PDAC, with implications for improving its early detection in individuals at risk.

101

### 102 Introduction

103

Pancreatic cancer (PC) remains lethal with approximately 500,000 new cases diagnosed globally each year with a comparable number of deaths. Pancreatic ductal adenocarcinoma (PDAC) ranks as the seventh primary cause of cancer-related mortality (1, 2). Projections suggest that by 2030, mortality rates from PDAC will exceed that of other prevalent cancers, a shift which is attributed to an increasing incidence of obesity, diabetes mellitus, alcohol consumption in some regions (Europe, North America,

and Oceania) and advancements in detection and institution of screening initiatives that facilitate the timely identification of more common cancers (1-3). Across the European Union and the United Kingdom, mortality rates of PDAC have surpassed lung, breast and prostate cancers, underscoring the pressing need for enhancements in strategies for both detection and treatment of PC (4). These improvements are crucial to mitigate the growing burden of this disease (5, 6).

114

115 The overall 5-year survival for PC patients is less than 10%. These figures improve in patients 116 diagnosed with pre-invasive lesions (intraepithelial neoplasia, mucinous cystic lesions) or small tumours 117 (< 2cm) detected at a localised stage (7). Patients with resectable disease are only identified in less 118 than 20% of cases and advances in early detection strategies hold potential for improving these dismal 119 figures (8, 9). The relatively low incidence and lifetime risk for PC in the general population (1.3%) 120 preclude asymptomatic, average-risk adult (>50 age) screening, and efforts are rather focused on high-121 risk populations (9-11). Internationally, screening and surveillance is therefore recommended only in 122 high-risk individuals (genetically predisposed, family history and high-risk pancreatic cysts), where a 123 lifetime risk of at least 5% justifies their surveillance (9, 10, 12, 13). While surveillance in these high-124 risk cohorts is consensus, we also reported on symptomatic cohorts in which the increased risk could 125 justify investigations, as an additional risk group (9, 14).

126

Existing evidence regarding the effect of timely diagnosis on outcomes in PDAC are limited, mostly due to the lack of randomisation, appropriate statistical considerations and homogenisations of study populations, and the topic remains an area of strong debate (15). Yet with research indicating that PDAC progresses from early (T1) stage to advanced (T4) in just over a year, and larger pancreatic cancers (>2 cm) metastases are detectable within approximately 3.5 months (range between 1.2 to 8.4 months), it is very likely that prompt identification of PC would improve its prognosis (15-17).

133

The reality of the situation however is that disease rarity, the presence of non-localising symptoms, the relatively low positive predictive values even for cancer specific 'red-flag' and advanced symptoms (e.g. weight loss, painless jaundice of 4-13%) challenge timely recognition in primary care settings, and a substantial number of PC patients are diagnosed following prolonged periods of clinical uncertainty (18, 19). Previous case-control primary care studies associated various abdominal symptoms and increased

139 frequency of primary care consultations with PDAC, over the two years preceding its diagnosis (14, 20,

140 21). These data suggest another potential window of opportunity for acceleration of PC detection.

141

142 In roughly 30% of patients, PC manifests in the form of jaundice indicating tumour induced biliary 143 obstruction, which is more evident in pancreatic head tumours (22). Together with significant weight 144 loss, these frequently represent an already advanced disease. Although most often explained by benign 145 aetiologies, symptoms such as back or epigastric pain, dyspepsia, anorexia, bloating, changes in 146 consistency of stool, weight loss and anxiety/depression may also indicate an underlying pancreatic 147 malignancy (14, 20-23). Such symptoms in adults (age > 60 years) with lifestyle factors (including heavy 148 alcohol and tobacco consumption, obesity) and on the background of new or long-standing diabetes 149 and chronic pancreatitis, are worrisome (9, 14, 21). In such patients, the United Kingdom National 150 Institute for Health and Care Excellence (NICE) recommends direct access to cross-sectional imaging 151 by CT, FDG-PET/CT, or EUS within two weeks (24). Although shorter diagnostic intervals are 152 associated with extended survival, the non-specific clinical presentation and the complexity of 153 diagnostic pathways result in delayed referral to specialised centres (14).

154

155 To accelerate and improve cancer detection rates in the UK, 'electronic cancer decision support tools' 156 (eCDST) have been developed to support primary care clinicians in fast tracking investigations in cases 157 of suspected cancer (25-27). Risk prediction models/algorithms such as QCancer (25-27) combine 158 symptoms data, patient risk factors and laboratory tests to predict a risk of undiagnosed cancers of 159 various anatomical sites (colon, pancreas, renal, gastro-oesophageal and ovarian). These are digitally 160 available for primary care physicians through patient record and data management portals (such as 161 EMIS Web and INPS) and where higher risk justifies further investigations, could be combined with 162 blood biomarker panels for further risk stratification prior to more invasive workup.

163

164 When suspected, establishing a diagnosis will involve measurement of the serum marker CA19-9, 165 cross-sectional (computed tomography or magnetic resonance) imaging and histopathology 166 (endoscopic ultrasound guided tissue biopsy; EUS-FNB). CA19-9 is most reliable as a marker of tumour 167 resectability, prognosis and monitoring of disease progression (28, 29), but as a diagnostic marker it 168 performs poorly (median sensitivity and specificity of ~80%; AUC= 0.82), particularly in stage I/II disease

169 and in Lewis body negative patients (30, 31). The development of reliable and accurate diagnostic 170 biomarkers is essential for risk stratification and prioritisation of further investigations, as well as 171 justification of invasive interventions where the findings on imaging are unequivocal (32). 172 173 Using serum samples collected from a selected study cohort with benign pancreatic and biliary tract 174 conditions and applying robust machine learning stacked modelling, we therefore developed a serum 175 biomarker signature capable of differentiating PC patients from healthy individuals and patients with 176 benign abdominal conditions presenting with non-specific yet concerning symptoms for pancreatic 177 cancer, at higher rates than CA19-9 and other state-of-the-art biomarkers.

- 178
- 179

#### 180 **Materials and Methods**

181

#### 182 **Study Design**

183 As our cohort, we used serum samples from the Accelerated Diagnosis of neuro Endocrine and 184 Pancreatic TumourS (ADEPTS) study (33) (UCL/UCLH Research Ethics Committee reference 185 06/Q0512/106, IRAS Number 234637, NIHR portfolio no. 7343) study - an early detection study aimed 186 at detecting pancreatic cancer in patients at an earlier stage. As part of the Early Diagnosis Research 187 Alliance (EDRA), the ADEPTS study (previously referred to as TRANSlational research in BILiary tract 188 and pancreatic diseases (TRANSBIL) study), commenced in 2018 and included a multicentre 189 prospective blood sample collection from patients with non-specific but concerning symptoms 190 associated with PDAC. Patients were recruited at gastroenterology/hepatobiliary and surgical clinics at 191 University College London (UCLH) and the Royal Free Hospitals (RFH), London, UK. Blood samples 192 were collected from subjects with benign hepatobiliary conditions as well as those with PDAC (stages 193 I-IV). All patients recruited to the ADEPTS study provided written informed consent.

194 For PDAC patients, tumour staging was performed according to the AJCC 8<sup>th</sup> edition (TNM) based on 195 cross-sectional imaging and for those undergoing surgery, based on multi-disciplinary team recordings. 196 All included PDAC cases were histologically confirmed by UCLH and RFH local pathologists based on

197 tissue analysis obtained by endoscopic ultrasound guided fine needle biopsies or specimens obtained198 during surgical resection.

199 For benign disease controls, patients were selected to include the following diagnoses: chronic 200 pancreatitis, intraductal papillary mucinous neoplasms (IPMN), or benign pancreatic diseases (e.g., 201 serous cystadenomas and pancreatic heterotopia). Patients with acute and chronic pancreatitis, 202 pancreatic cysts, benign biliary duct diseases (e.g., IgG4 disease), liver disease, gastritis/reflux disease, 203 gallstones as well as those with familial history of pancreatic cancer, were also used. Samples also 204 included those collected from patients presenting with non-specific symptoms which were not otherwise 205 explained by an underlying gastrointestinal pathology (such as non-specific abdominal pain and irritable 206 bowel syndrome) as well as other malignancies. Medical history and confirmation of diagnosis was 207 obtained from hospital medical records and included GP and secondary clinic referral letters. For 45 208 patients, a QCancer score was available at time of specialist centre consultations. QCancer calculates 209 the probability of an individual as harbouring an existing, yet undiagnosed cancer, by considering their 210 specific risk factors and presenting symptoms. These are digitally available for primary care physicians 211 through patient record and data management portals such as EMIS Web and INPS and designed as 212 clinical decision support tools to aid in assessment of need for specialist referrals (34).

213

214 To further represent the healthy population we also used samples from 72 healthy control UKCTOCS 215 (35) samples that were collected from a nested case control discovery study part of UKCTOCS reported 216 before (36), which had been previously approved by the Joint UCL/UCLH Research Ethics Committee 217 A (Ref. 05/Q0505/57). Written informed consent for the use of samples in the UKCTOCS trial and 218 secondary ethically approved studies was obtained from donors and no data allowing identification of 219 patients was provided. The original UKCTOCS dataset from which data was used here was derived 220 from serum samples collected from post-menopausal women, aged between 50 and 74 years, who 221 were recruited between the years 2001 and 2005 (35). The collection of these samples was conducted 222 in accordance with a specific Standard Operating Procedure (SOP) (37, 38). For the current work our 223 interest lies only with the UKCTOCS matched non-cancer controls, i.e., with no cancer registry code, 224 from individual women selected based on collection date, age, and centre to minimize variation due to 225 handling and storage. Comprehensive information regarding diabetes status for the selected UKCTOCS participants was either unavailable or incomplete. In addition, data on disease duration was 226

not accessible. Consequently, it was not feasible to stratify samples to discovery and validation sets
based on the type of diabetes they may have had. For the purposes of this study, only healthy controls
that were matched to PDAC cases, with less than one year to diagnosis, were utilized.

230

A total of 539 serum samples (493 controls and 46 PDAC cases, see Table 1) were analysed using the Olink multiplex immunoassay Oncology II panel in addition to five in-house markers: Carbohydrate antigen 19-9 (CA19-9), Interleukin 6 Cytokine Family Signal Transducer (IL6ST/IL6RB), von Willebrand factor (VWF), Pyruvate kinase isozymes M1/M2 (PKM/PKM2) and Thrombospondin 2 (THBS2/TSP2). The selection of additional markers, beyond CA19-9, was informed by our preceding research in early detection of PDAC (36, 39). In those studies, a panel of markers was identified due to its demonstrated ability to facilitate the early detection of pancreatic cancer, with a lead time of up to two years prior to diagnosis

- 238 diagnosis.
- 239 240

### 0 Serum analyte measurements

241

242 All ADEPTS (33) samples were randomized for testing. Supplementary Table 1 summarizes dilution 243 factors and coefficients of variation. CA19-9 was measured using the Mucin PC/CA19-9 ELISA Kit 244 (Alpha Diagnostic International) according to the manufacturer, using a 1:4 serum dilution. For VWF, 245 we resorted to the Von Willebrand Factor Human ELISA Kit (abcam) at a 1:100 serum dilution. 246 IL6ST/IL6RB by Quantikine human soluble gp130 (R&D Systems), according to manufacturer 247 recommendations, at a 1:100 serum dilution. THBS2/TSP2 was measured using the Quantikine Human 248 Thrombospondin-2 Immunoassay (R&D Systems) at a 1:10 serum dilution. Pyruvate kinase M2 (PKM2) 249 was measured with an ELISA (Cloud-Clone Corp) at a 1:10 dilution.

250

We outsourced tests using the multiplex immunoassay Oncology II panel from Olink on all samples. This Olink panel measured known cancer antigens, growth factors, receptors, angiogenic factors, and adhesion regulators (as detailed in Supplementary Table 2). Identical assays were performed on a subset of samples derived from the UKCTOCS study (37, 38).

255

To bridge the normalized protein expression values from Olink between the UKCTOCS and ADEPTs datasets, we selected a representative sample set of 16 from each cohort and plated them together.

258 Subsequently, a correction was applied to the datasets using the statistical algorithms recommended 259 in the Olink data normalization white paper (40). This method ensured that the data from different 260 batches and studies were comparable, thereby enhancing the robustness and validity of the findings.

261

#### 262 **Statistical analysis**

263

264 The selected set of ADEPTS samples used in this work was partitioned into two distinct sets: a discovery 265 subset, comprising two-thirds of the total sample size, and a validation subset, encompassing the 266 remaining one-third. Allocation into each set was performed by stratifying for specific age ranges, 267 diabetes status, PDAC status and control diagnosis class. For the PDAC cases, tumour stage was also 268 used. The age stratification ranges were the following: 18<Age≤28; 29<Age≤38; 39<Age≤48; 269 49<Age≤58; 59<Age≤68; 69<Age≤78; Age≥79. The samples assigned to the control class were made 270 of benign conditions such as: Sphincter of Oddi dysfunction, Pancreatic Cyst, Other Cancer, Other 271 Biliary Duct Disease, No Relevant Diagnosis, Liver Disease, Irritable Bowel Syndrome, IgG4 Disease, 272 Gastritis/Reflux Disease, Gallstone Disease, Familial Pancreatic Cancer, Chronic Pancreatitis, Acute 273 Pancreatitis, Isolated LFT Derangement and Non-specific Abdominal Pain. We also added an additional 274 set of healthy control samples collected from a nested study done in UKCTOCS samples used in a 275 previous paper (41). The controls matched by age to the PDAC cases in the UKCTOCS cohort that had 276 a time to diagnosis below up to one year were selected. The allocation of these controls to the discovery 277 or validation sets was done according to the division used in our previous work (41). The number of 278 controls and cases collected for this study can be visualized in Figure 1. UKCTOCS controls are 279 identified as 'Healthy'. The discovery-validation split puts the prevalence of PDAC in the discovery set 280 at close to 8%. The prevalence of PDAC in the resulting validation was approximately 14%.

281

282 Receiver operating characteristic (ROC) curves were constructed for each model to assess diagnostic 283 performance. The area under the curve (AUC) for the ROC curves was used as the metric. Models and 284 techniques were compared based on their rank in the discovery under a 10-time repeated 5-fold cross-285 validation resampling strategy. ROC curves were generated with the pROC R package (version 1.18.0, 286 https://cran.r-project.org/web/packages/pROC/index.html ). 95% CI for AUCs were determined by 287 stratified bootstrapping. All AUC confidence intervals crossing 0.5 were considered to be non-

significant. P values comparing ROC curves were also calculated using the *pROC* package, under a
 one-sided bootstrap approach with 10000 runs.

290

291 In order to evaluate the association between each of the single markers available for this work, including 292 clinical covariates (see Table 1 and Figure 1), and PDAC status, we used a logistic regression model 293 implemented in the logistf R package (https://cran.r-project.org/web/packages/logistf/index.html, 294 version 1.24.1). This approach fits a logistic regression model using Firth's bias reduction method. The 295 reported confidence intervals for odds ratios and tests were based on the profile penalized log likelihood 296 and incorporate the ability to perform tests where contingency tables are asymmetric or contain zeros. 297 The performance of single marker models was also verified in the discovery and validation sets (see 298 Supplementary Figure 1 and Supplementary Table 3 and 4). The same package was also used to verify 299 the association of the presence of symptoms and PDAC status (see Figure 4).

300

301 A comprehensive multi-dimensional examination of the collated data was conducted by employing two 302 distinct analytical frameworks. The first was a stacked ensemble algorithm where base-learners were 303 developed according to the same algorithm but in subsets of the discovery set where samples belonging 304 to a specific control diagnosis class were contrasted against the same 24 PDAC cases (see for example 305 the proportions in Figure 1). The resulting base-learners were then stacked by a logistic regression 306 model, (see Supplementary Table 5 for the resulting coefficients and Supplementary Figure 2 for the 307 stacking procedures). This approach aimed to leverage the predictive power of multiple models, thereby 308 enhancing the robustness and potentially leading to more precise predictive outcomes (36, 42, 43). For 309 each base-learner classifier we resorted to a Recursive Feature Elimination (RFE) routine with logistic 310 regression as the fitting algorithm available through caret (version 6.0-93, https://cran.r-311 project.org/web/packages/caret/index.html) and oversampling of the minority class. This secures robust 312 selection of features when combined with cross validation and the selection process is encapsulated 313 inside an outer layer of resampling (44-46). Due to the prevalence of PDAC cases in the whole 314 dataset being low, random under sampling of the majority class, here benign and healthy controls, 315 would not have been sufficient to meet the demands of most algorithms. Therefore, creating an 316 ensemble of classifiers specialised in contrasting a specific diagnostic class against PDAC allowed 317 us to create more balanced subsets leading to increased performance (Figure 2). For the samples

318 collected from UKCTOCS no symptoms information was available and, therefore, we created a 319 separate classifier associated with this subset of individuals.

320

321 In addition to the stacked approach we also fitted state-of-the-art algorithms such regularized random 322 forests (RRF, version 1.9.4, https://cran.r-project.org/web/packages/RRF/index.html); extreme 323 gradient boosting trees (xgbTree, version 1.6.0.1, https://cran.r-324 project.org/web/packages/xgboost/index.html ); and a generalized linear model with RFE applied to 325 the whole discovery set (RFE glm, in caret). The latter allowed for testing if the division into diagnosis 326 specific classifier ensembles was advantageous at low but representative prevalence (Figure 2) in 327 a situation where we want to contrast PDAC cases with confounding diseases in a clinical setting. 328 All base-models were trained by 10 times repeated 5-fold cross-validation with over-sampling of the 329 minority class (see Table 1 and Supplementary Tables 6 and 7 for information on prevalence).

330

331 To verify if the PDAC index developed with the ensemble stacked approach had any association with 332 metrics used in the clinic but not taken into account in any stage of algorithm training, we also gathered 333 the QCancer score (47) for individuals in the ADEPTS study (see Figure 6).

334

335 The procedure for assessing feature importance in each base learner was a model-agnostic method 336 based on a simple feature importance ranking measure (48), implemented in the R package vip (version 337 0.3.2, https://cran.r-project.org/web/packages/vip/index.html). The model-agnostic interpretability, by 338 decoupling the interpretation from the model itself, introduces a level of flexibility that enables its 339 application across any supervised learning algorithm. Despite the algorithm used for each diagnosis-340 specific classifier being the same, the model-agnostic approach allows us to be able to generalise the 341 computed importances to other work in the literature.

342

343 Enrichment analysis for each of the signatures developed was performed with the *gprofiler2* R package 344 (version 0.2.1, https://cran.r-project.org/web/packages/gprofiler2/index.html ). A threshold for multiple

345 comparison correction under the framework of false discovery rate was instituted at 0.05.

346

#### 348 Results

#### 349 **Data set characteristics**

350 In the full set of samples collected from the ADEPTS cohort, age at the time of sample collection, 57.44 351 (range from 19.00 to 93.00) for controls and 69.72 (range from 43.00 to 91.00) for PDAC cases, emerged as a 352 risk factor (OR= 1.06 (95% Cl 1.04 – 1.09), p= $2.47 \times 10^{-7}$ ) (Table 1). As a predictor in a logistic regression 353 model age as a feature achieved a ROC AUC of 0.73 (95% CI 0.66-0.79), with a cut-off at 61.5 years 354 (calculated using the Youden J statistic). This finding was also observed in both the discovery 355 (Supplementary Table 6 and Figure 1, ROC AUC 0.74 (95% CI 0.64-0.83), cut-off at 70) and validation 356 sets (Supplementary Table 7 and Figure 1, 0.74 (95% CI 0.64-0.82), cut-off at 60), which incorporated 357 not only ADEPTS samples but also healthy control samples collected from UKCTOCS (35). In our past 358 research which was focused exclusively on UKCTOCS longitudinal samples, age similarly emerged as 359 a risk factor for PDAC (36). Furthermore, gender (OR=2.72 (95% CI 1.46 - 5.27), p=0.0015) and 360 ethnicity taken as a one-hot encoded variable (OR=2.02 (95% CI 1.34 - 3.03), p= $6.56 \times 10^{-4}$ ) were also 361 confirmed as significantly associated with an increased risk of PDAC (Table 1). In the whole set of 362 samples collected from the ADEPTS cohort, men had a 2.72-fold risk of PDAC compared to their female 363 counterparts. Individuals of Caucasian ethnicity demonstrated a decreased risk of PDAC in a one 364 versus rest calculation (OR=0.38 (95% CI 0.20 - 0.69), p=0.0018) and no significant association was 365 found between PDAC risk and Asian or Afro-Caribbean ethnicity in the ADEPTS dataset under the 366 same modelling framework (Table 1). The association of gender and PDAC was also confirmed in the 367 discovery (OR=4.98 (95% CI 2.08 - 13.50), p=0.00023, Supplementary Table 6 and Figure 1) and 368 validation sets (OR=2.65 (95% CI 1.11 – 6.58), p=0.028 Supplementary Table 7 and Figure 1), but 369 ethnicity, taken as a one-hot encoded variable, remained a significant predictor of PDAC only in the 370 validation set (OR=2.66 (95% CI 1.42 - 5.17), p=0.0020) (Supplementary Table 7 and Figure 1), which 371 as was highlighted above also includes healthy control UKCTOCS samples. Within the group of the 372 clinical covariates only age and gender are significant predictors of PDAC in both the discovery and 373 validation set (Figure 1), with only age achieving a significant AUC in the validation set between these 374 two. However, this was concomitant with remarkably low sensitivity (Sens), positive predictive (PPV) 375 value and negative predictive value (NPV) at 90% specificity (Spec): AUC 0.74 (95% CI 0.64-0.82), 376 Sens 0.13 (95% CI 0 - 0.39), PPV 0.16 (95% CI 0 - 0.36), NPV 0.88 (95% CI 0.86 - 0.91).

#### 377 Development of PDAC biomarker signature in the presence of confounding conditions

378 To aid the early detection of this cancer in individuals at risk, we aimed to develop a biomarker signature 379 that could be used to differentiate between suspected PDACs and benign biliary conditions that often 380 overlap in clinical presentation. We applied a uniquely developed ensemble learning model, with a 381 logistic regression stacking layer (see Supplementary Figure 2 and statistical analysis in the Methods 382 section), to a set of 539 serum samples (493 controls and 46 PDAC cases) which were analysed using 383 the Olink Oncology II panel as well as four additional biomarkers we previously reported on (36). These 384 included IL6ST, VWF, THBS2 and CA19-9. The oncogenic and prognostic glycolytic enzyme PKM2 385 was additionally selected based on our past report of its diagnostic utility in biliary tract cancer patients 386 (49-51).

387 The application of stacked ensemble modelling as presented herein bolsters the robustness of 388 predictive outcomes, enhancing the performance of biomarker panels through the incorporation of 389 serum biomarker levels and relevant clinical covariates for distinct diagnostic classes. Each component 390 classifier within the ensemble is designed to provide a specialized distinction between confounding 391 diagnoses and PDAC, thereby establishing a heterogeneous set of classifiers that facilitates the precise 392 identification of PDAC (see statistical analysis section in Methods). Previous studies have attested to 393 the beneficial role of ensemble methods in augmenting early detection of PDAC against only healthy 394 controls (36). The implementation of stacked (Stack, Figure 2), specialized classifiers, developed within 395 the discovery set, generated a biomarker signature capable of predicting PDAC with an AUC of 0.98 396 (95% CI 0.98 - 0.99), sensitivity of 0.99 (95% CI 0.98 - 1), PPV 0.92 (95% CI 0.91 - 0.92) and NPV 397 0.99 (95% CI 0.97 - 1) at 90% specificity. In contrast, the predictive efficacy of CA19-9 in the discovery 398 set taken as a single predictor under a logistic regression model was 0.79 (95% CI 0.66 - 0.91) 399 (p=0.0016 under a one-sided bootstrap test comparing the two AUCs), sensitivity 0.67 (95% CI 0.50 -400 0.83), PPV 0.32 (95% CI 0.26 - 0.38) and NPV of 0.97 (95% CI 0.96 - 0.99) at 90% specificity (see 401 Supplementary Table 3). Amongst all biomarkers, CA19-9 demonstrated the most significant 402 association (refer to Supplementary Table 3 and Supplementary Figure 1 for univariate trend 403 associations across the discovery set), and one of the highest performances in the validation set 404 (Supplementary Figure 1 and Supplementary Table 4).

406 In the validation set, the ensemble signature predicted PDAC with an AUC of 0.95 (95% CI 0.91 – 0.99), 407 sensitivity 0.86 (95% CI 0.68 - 1), PPV 0.54 (95% CI 0.48 - 0.58) and NPV of 0.98 (95% CI 0.95 - 1) at 408 90% specificity. Once again, this is an improvement with respect to CA19-9 (p=0.0082, one-sided 409 bootstrap test) taken as a univariate model developed in the discovery set; this CA19-9 model predicted 410 PDAC status with an AUC of 0.80 (95% CI 0.66 - 0.93), sensitivity 0.65 (95% CI 0.48 - 0.56), PPV 411 0.49 (95% CI 0.41 - 0.56) and NPV of 0.95 (95% CI 0.92 - 0.98) at 90% specificity in the validation 412 set. If we further validate only on the benign disease controls and PDACs collected from ADEPTS, the 413 diagnostic-specific ensemble signature achieved an AUC of 0.96 (95% CI 0.92 - 0.99), sensitivity 0.82 414 (95% CI 0.64 - 0.95) at 90% specificity. This performance is also significantly higher than the 415 performance of CA19-9 in a univariate model: AUC of 0.79 (95% CI 0.64-0.93) (p= 0.013 when 416 compared with the full signature, one-sided test) and sensitivity of 0.18 (95% CI 0.03 - 0.69).

417 A closer examination of the individual performances of each base-learner classifier (Figure 2A and B) 418 reveals that the logistic regression stacked ensemble approach has superior performance in both 419 discovery and validation sets. Despite the best base-learner being trained on samples diagnosed as 420 'Gastritis/Reflux Disease' (Figure 2A and B), its performance was also superseded by the AUC 421 computed with the stack model, the logistic regression coefficients of which are delineated in 422 Supplementary Table 5. The stack model significantly relies on the "Healthy", "Chronic Pancreatitis", 423 "IgG4 Disease", "Irritable Bowel Syndrome", 'Other Biliary Duct Disease", "Sphincter of Oddi 424 Dysfunction", "No Relevant Diagnosis", "Other Cancer" and "Pancreatic Cyst" base-learners. Even 425 though the remaining diagnostic class base-learners, including "Gastritis/Reflux Disease", did not reach 426 statistical significance (p<0.05), employing a stack that solely resorts to significant base-learners led to 427 a reduction in generalization capacity: AUC 0.98 (95% CI 0.97 - 0.99), sensitivity 0.98 (95% CI 0.95 -428 1), PPV 0.92 (95% CI 0.91 – 0.92), NPV 0.97 (95% CI 0.94 – 0.99) in the discovery set; AUC 0.93 (95% 429 CI 0.87 – 0.99), sensitivity 0.82 (95% CI 0.64 – 0.95), PPV 0.53 (95% CI 0.47 – 0.57), NPV 0.97 (95% 430 CI 0.95 – 0.99) in the validation set. Although the differences are not substantial, we retain the full set 431 of base-learners to enhance the generalization capacity for predicting PDAC in unseen data sets and 432 new samples.

434 The employment of stacked diagnosis-specialized classifiers surpassed the AUC performance of state-435 of-the-art algorithms such as random forests (RRF) and extreme gradient boosting methods (xgbTree), 436 in terms of AUC, sensitivity, positive predictive value, and negative predictive value at 90% specificity 437 (Figure 2C and D); although the performance AUC of the stacked classifier was only marginally 438 significantly higher than that obtained with RRF (p=0.040, one-sided) and not significant when 439 compared with xgbTree (p=0.26, one-sided), the sensitivity values at 90% specificity obtained with the 440 alternative methods were, in fact, significantly lower, p=0.028 and p=0.045, respectively. The ensemble 441 also outperformed a logistic regression model with recursive feature elimination (Figure 2C and D) that 442 did not rely on ensemble modelling (p=0.0066, one-sided), further substantiating our choice of machine 443 learning paradigm for facilitating the identification of PDAC cases in a clinical setting where confounding 444 diagnoses may be present, and the prevalence is low.

445

446 The comprehensive index signature, incorporating all diagnostic categories, was constituted by 49 447 features, of which 44 were proteins (see Figure 3 for the importance associated with each). Among 448 these proteins, 21 demonstrated a significant association with PDAC in the discovery set; ICOSLG, 449 GPNMB, ESM-1, DLL1, VWF, ERBB2, FCRLB, CEACAM5, EGF, CTSV, FASLG, Creatinine, CPE, 450 CA9/CAIX, TBIL, CD207, CRP, CDKN1A, EPHA2, ITGAV, and MUC-16 (see Supplementary Figure 1 451 and Supplementary Tables 3). The remaining 23 proteins, namely CXCL13, ERBB3, FOLR1/FR-alpha, 452 FADD, ERBB4, CD27, AREG/AR, ADAM-TS-15, ABL1, ANXA1, CXCL17, CD70, CEACAM1, CD48, 453 IL6ST, CD160, PKM/PKM2, CYR61/CCN1, CRNN, ADAM-8, FOLR3/FRgamma, THBS2, GZMB, did 454 not demonstrate a significant association with PDAC in univariate models (see Supplementary Figure 455 1 and Supplementary Tables 3 and 4). Additionally, five clinical covariates—Gender, Age, Ethnicity, 456 Diabetes, and Body Mass Index (BMI)-were identified as important predictors following 457 comprehensive recursive feature elimination during cross-validation (Figure 3).

458 Gene Ontology (GO) and biological pathway enrichment (Kyoto Encyclopaedia of Genes and 459 Genomes; KEGG, Reactome Pathway Database; REAC and WikiPathways; WP) analysis was 460 performed for the selected set of features using g:Profiler (Supplementary Figure 3). Top significant 461 terms for biological processes (BP) included 'circulatory system development', 'blood vessel 462 morphogenesis', 'cell adhesion', 'angiogenesis', 'blood vessel development', 'regulation of cell 463 adhesion', 'positive regulation of cell population proliferation', 'cell-cell adhesion', and 'regulation of

464	developmental process'. Top relevant biological pathways included: 'PI3K-KAT signalling pathway',
465	'ERBB signalling pathway', 'pathways in cancer', 'proteoglycans in cancer', 'platinum drug resistance',
466	'prostate cancer', 'type I diabetes mellitus', 'MAPK signalling pathway' and 'focal adhesion'.

467

The scaled importance of each feature and diagnostic class/classifier is depicted in Figure 3. It is of significance to note that not every biomarker was selected by each individualized classifier, highlighting the requirement for an array of diverse predictors, each tailored to specific underlying conditions, to effectively identify PDAC. This is consistent with the idea that heterogeneous ensembles are fundamental for predictive capacity in blind datasets (36, 43).

473

474 Of the five selected clinical covariates, only Age, Ethnicity, and Gender manifested as significant 475 predictors of PDAC in the validation set, as illustrated in Figure 1 and explained in the data set 476 characteristics subsection (see also Supplementary Table 6 and 7). It is worth emphasizing that the 477 lack of significant association between certain markers and PDAC in the discovery set does not 478 preclude their inclusion in the signature. These variables were selected due to their contribution to the 479 enhanced robustness and generalization capacity in predicting PDAC during cross-validation with a 480 recursive feature elimination routine (see Methods). A similar trend was verified in prior work focussed 481 on ensemble models for PDAC early detection against healthy controls (36).

482

483 Application of a reduced, 8-marker signature as a differentiator of PDAC from healthy and
 484 benign controls

485

Across all conditions, 8 features with relatively higher scaled importance that differentiated controls from PDAC patients were selected (Figure 3). Importance is measured by the contribution of a specific feature to the output of the model (see Methods), in our case the probability of PDAC. These included CA19-9, VWF, CPE, CTSV, CEACAM1 and CD160 together with Diabetes and Age as clinicodemographic variables. Diabetes was a predictor of the differences between PDAC against familial cases, gastric reflux disease (GORD), sphincter of oddi (SOD) dysfunction, as well as healthy controls.

494 CA19-9 levels were only selected as a top discriminating feature against PDACs in patients with 495 suspected sphincter of Oddi dysfunction, benign liver disease, irritable bowel syndrome (IBS), those 496 with isolated LFT derangements as well as distinguished healthy subjects and those with other cancers 497 (Figure 3 and Supplementary Table 8), from PDAC patients.

498

Von Willebrand Factor (VWF) levels differentiated PDAC from symptomatic patients with pancreatic
cysts, benign biliary duct diseases, non-abdominal conditions, patients with family history of PDAC,
those with GORD as well as healthy subjects.

502

The immunoglobulin like surface antigen molecule CD160 (peripheral natural killer cells and CD8<sup>+</sup> T lymphocytes) (52) and a proposed immune checkpoint inhibitor, was selected as a significant differentiator of PDAC from benign biliary tract diseases (IgG4 disease), SOD dysfunction, IBS as well as in familial pancreatic cancer subjects and other cancers. Cathepsin V (CTSV) levels were also a predictor of multiple conditions against PDAC, including benign biliary diseases and in subjects belonging to the familial PC cohort. In healthy subjects, however, this feature did not show significant importance as a differentiator from PDAC.

510

Serum levels of the metallo-carboxypeptidase E (CPE) were a feature selected as significant in five conditions (acute pancreatitis, gallstones and IgG4 disease, SOD dysfunction and GORD) as well as a differentiator in those with FH of PC. A higher scaled importance was attributed to this enzyme against CA19-9 when differentiating acute and chronic pancreatitis (CP), isolated LFT derangements, unexplained abdominal pain and non-abdominal conditions versus PDAC (Figure 3).

516 THE CEA cell adhesion molecule (CEACAM1) was selected as a feature in patients with non-explained 517 recurrent abdominal pain, isolated LFT derangements, GORD, SOD dysfunction as well as a feature 518 selected against non-pancreatic cancers.

519 Chronic pancreatitis (CP) is a known risk factor for PDAC. In our index signature, the protein markers 520 selected against PDAC included ESM1, ICOSLG, CTSV, CXL17 (CXC motif chemokine ligand 17), 521 IL6ST, ITGAV, GZMB (granzyme B; secreted serine protease), with a reduced risk for cancer in 522 Caucasian ethnicity (53-55).

523

524

525 We therefore opted to assess their combined performance against CA19-9 as a single marker. Using a 526 similar stacking procedure as before, a reduced model was trained using the same ensemble approach 527 as that highlighted before but with only 8 features as the input. The reduced signature predicted PDAC 528 still with a high AUC value of 0.97 (95% CI 0.95-0.98), sensitivity 0.98 (95% CI 0.95-1), PPV 0.92 (95% 529 CI 0.91-0.92) and NPV of 0.98 (95% CI 0.94-1) at 90% specificity, in the discovery set (Supplementary 530 Figure 4C). In the validation set, however, the performance of the 8-marker signature was significantly 531 reduced (p= 0.00038, one-sided) compared to the full stacked model (AUC of 0.84 (95% CI 0.75-0.94), 532 sensitivity 0.64 (95% CI 0.36-0.82), PPV 0.47 (95% CI 0.33-0.53) yet with a NPV of 0.95 (95% CI 0.91-533 0.97) at 90% specificity (Supplementary Figure 4D)), and only marginally superior to CA19-9 as a single 534 marker (p=0.18, one-sided). On the other hand, the 8-marker signature still outperformed CA19-9 by a 535 relatively large margin when predicting PDAC against healthy UKCTOCS controls in the validation set: 536 AUC<sub>redsig</sub> of 0.93 (95% CI 0.84 - 1), sensitivity<sub>redsig</sub> of 0.86 (95% CI 0.54 - 1), PPV<sub>redsig</sub> 0.94 (95% CI 0.90 537 - 0.94), NPV<sub>redsig</sub> 0.80 (95% CI 0.54 - 1); AUC<sub>CA19-9</sub> of 0.84 (95% CI 0.70 - 0.97), sensitivity <sub>CA19-9</sub> of 538 0.68 (95% CI 0.5 - 0.91), PPV CA19-9 0.92 (95% CI 0.89 - 0.94), NPV CA19-9 0.62 (95% CI 0.52 - 0.85), 539 at 90% specificity. Under a bootstrap test this AUC difference is significant p= 0.025 (one-sided). In 540 addition, it also outperformed the full PDAC ensemble model when predicting PDAC against healthy 541 controls in the validation set, although the differences were not significant (p=0.2, one-sided): AUC<sub>sig</sub> of 542 0.90 (95% CI 0.77 – 1), sensitivity<sub>sig</sub> of 0.86 (95% CI 0.54 – 1), PPV<sub>sig</sub> 0.94 (95% CI 0.92 – 0.94), NPV<sub>sig</sub> 543 0.80 (95% CI 0.66 - 1) at 90% specificity.

544

545 If on the other hand the reduced signature is validated in ADEPTS samples only, i.e. in PDACs plus 546 benign disease controls, the performance of the reduced signature is far inferior to the full signature: 547 AUC<sub>redsig</sub> of 0.83 (95% CI 0.73 - 0.93) (p= 0.0009 when compared with AUC<sub>sig</sub>, one-sided test), 548 sensitivity<sub>redsig</sub> 0.59 (95% CI 0.27 - 0.82), PPV<sub>redsig</sub> 0.47 (95% CI 0.29 - 0.55) and NPV<sub>redsig</sub> 0.94 (95% 549 Cl 0.89 - 0.97), at 90% specificity. This further justifies the use of the full ensemble signature in blind 550 data sets and in a scenario where there is limited information on a patient trajectory, despite its 551 increased complexity.

In consideration of the marker importance in the reduced model, no marker received a null significance across all diagnostic specific base-learners, a divergence from observations in the comprehensive signature. CA19-9 emerged with the largest average importance across conditions, which also contrasted with the full model. Age and VWF were ranked with elevated average significance across diverse conditions. It's pertinent to note that CPE levels manifested diminished scaled importance in discerning healthy controls from PDAC, particularly when juxtaposed against CA19-9, age, and CEACAM1 (refer to Supplementary Figure 5).

559

### 560 Application of the full PDAC ensemble signature in symptomatic patients

561 Our subsequent aim was to explore whether specific clinical manifestations were correlated with PDAC 562 status in our ADEPTS patient cohort, for which such information was available (refer to Supplementary 563 Figure 6 and Supplementary Table 9). As a similar type of data was not available for the UKCTOCS 564 subset (healthy controls) used in this work, we focussed this section on the ADEPTS cohort.

565

566 In our prior research, we analysed 12 "red-flag" symptoms reported by patients up to 22 months before 567 the diagnosis of pancreatic cancer was established (20). In this work, 'Vomiting' (p=0.17), 568 'Asymptomatic LFT Derangement' (p=0.28), 'Back pain' (p=0.54), 'Change in Bowel Habit' (p=0.67) and 569 'Rectal Bleeding' (p=0.76) were selected for PDAC (versus benign disease controls), yet only 'Jaundice' 570  $(p=3.22\times10^{-15})$ , and 'Weight Loss'  $(p=1.44\times10^{-6})$  were significantly associated with PC cancer cases in 571 the set of samples randomly selected from the ADEPTS cohort, in which the biomarker panel was tested 572 (Figure 4B and Supplementary Table 9). Unsurprisingly, 'Reflux' (p=0.022) and 'Bloating' (p=0.048) 573 were significantly associated with benign controls. Interestingly, 'Abdominal Pain', 'Heartburn', 574 'Anaemia', and 'Dysphagia' upon presentation were aligned more with the benign control cohort, albeit 575 not significantly (refer to Figure 4 and Supplementary Table 9).

576

577 Within the framework presented in preceding sections, our ensemble of classifiers was developed 578 independently of symptomatic data. To assess the overall efficacy of our signature and its predictive 579 capacity for PDAC, we scrutinized its performance on a subset of ADEPTS patients, belonging to both 580 discovery and validation cohorts, manifesting with 'Weight Loss' (n=56) and 'Jaundice' (n=40) (refer to

581 Figure 4 and Supplementary Table 9). For each sample within these cohorts, where symptom data was 582 accessible, probability scores were derived based on the ensemble model formulated using the whole 583 discovery set presented above. We should emphasize that no additional model refinement was 584 pursued. The decision to aggregate these probability scores is further rationalized by the relatively 585 limited patient count exhibiting 'Weight Loss' and 'Jaundice' within the individual discovery and 586 validation datasets (Supplementary Table 9). In the ADEPTS subset of samples presenting with 'Weight 587 Loss', an AUC of 0.95 (95% CI 0.90 - 0.1), a sensitivity of 0.94 (95% CI 0.29 - 1), a PPV of 0.80 (95% 588 CI 0.56 - 0.81), and a NPV of 0.97 (95% CI 0.74 - 1) at 90% specificity were achieved (Table 2 and 589 Figure 5). In patients presenting with 'Jaundice', an AUC of 0.89 (95% CI 0.79 - 0.99), a sensitivity of 590 0.73 (95% CI 0.36 - 0.91), a PPV of 0.90 (95% CI 0.82 - 0.92), and a NPV of 0.73 (95% CI 0.54 - 0.89), 591 at 90% specificity, were observed (Table 2 and Figure 5). Compared with the AUC obtained with a 592 simple CA19-9 logistic regression model developed in the discovery set and by concatenating the 593 probability scores in the discovery and validation as done above, a significantly lower AUC of 0.74 (95% 594 CI 0.58 - 0.90) is achieved (p=1.29×10<sup>-11</sup>, one-sided bootstrap test), with a sensitivity of 0.53 (95% CI 595 0.24 - 0.76), a PPV of 0.70 (95% CI 0.50 - 0.77), and a NPV of 0.81 (95% CI 0.73 - 0.90), at 90% 596 specificity, for patients presenting with 'Weight Loss'. For patients presenting with 'Jaundice' an AUC of 597 0.70 (95% CI 0.53 - 0.86) is reached, also significantly inferior ( $p=1.94\times10^{-7}$ ), with a sensitivity of 0.41 598 (95% CI 0.14 - 0.73), a PPV of 0.83 (95% CI 0.64 - 0.90), and a NPV of 0.55 (95% CI 0.46 - 0.73), at 599 90% specificity, for CA19-9 as the single predictor.

600

601 With respect to other non-localising symptoms of note (Figure 5, Table 2 and Supplementary Table 10), 602 the best predictive performance was noted for the full index signature where it was able to differentiate 603 patients presenting with 'abdominal pain' due to benign conditions vs. PDAC with an AUC of 0.98 (95% 604 CI 0.97-1), sensitivity of 0.94 (95% CI 0.81-1), PPV 0.43 (95% CI 0.40-0.45) and a NPV of 0.99 (95% 605 CI 0.98-1), at 90% specificity. In those presenting with 'change in bowel habit', an AUC of 0.97 (95% CI 606 0.92-1), sensitivity 0.86 (95% CI 0.81-1), PPV of 0.51 (95% CI 0.41-0.55) and NPV of 0.98 (95% CI 607 0.95-1) was obtained. Both the index and the 8-marker signature showed superior predictive 608 performance to CA19-9 as a single marker (see Supplementary Table 11 for the respective p-values).

- 609
- 610

#### 611 Correlation of the full PDAC ensemble signature with QCancer pancreatic score

612

613 In our final analysis, we juxtaposed the performance of our full ensemble classifier PDAC index against 614 the QCancer risk prediction index, a clinical decision support tool available for primary care physicians, 615 that integrates a myriad of individual-specific risk factors including age, sex, ethnicity, clinical 616 measurements, diagnoses, and patient-reported symptoms into a risk stratifying point of care 617 questionnaire (47). The 'Today's QCancer' index evaluates an individual's current risk of having an 618 undiagnosed cancer as well as the specific risk for 9 distinct underlying cancer types, including 619 pancreatic ('pancreatic' score) (56, 57). The aim was to determine whether in combination, the QCancer 620 eCDST and our biomarker index signature would be able to better discriminate PDAC patients in a 621 symptomatic (ADEPTS) cohort or whether it would be redundant. As the current risk threshold set by 622 the NICE is at 3% for triggering specialist referrals (24), we opted to assess the combined performance 623 of our index signature and the eCDST at a same or lower cut-off values.

624

625 The number of samples for which a QCancer score was computed is illustrated in Figure 6C. Using the 626 diagnostic-specific ensemble model delineated previously, probability scores for samples in both 627 discovery and validation cohorts were used to ascertain the combined ROC AUC for those samples 628 possessing a QCancer score. This amalgamation was imperative, considering the reduced number of 629 samples with an associated QCancer score (Figure 6C). It should be emphasized that no subsequent 630 refinements or training of the algorithm were conducted. The ensemble stack index demonstrated a 631 remarkable performance, achieving an AUC of 0.98 (95% CI 0.97 - 0.99), a sensitivity of 0.99 (95% CI 632 0.97-1), a PPV of 0.91 (95% CI 0.90 - 0.91), and a NPV of 0.99 (95% CI 0.96 - 1), at 90% specificity. 633 Interestingly, when considering only samples with a QCancer risk above 2 or 2.5, the biomarker and 634 clinical covariate ensemble index exhibited comparatively lower performance (Figure 6A). For a 635 QCancer risk above 3.0, the performance of the index decreases minimally once again, which is 636 expected as the difficulty of correctly singling out cases from confounding controls is increased (Figure 637 6A). However, the QCancer pancreatic score did exhibit a correlation with the odds of PDAC as 638 determined by the ensemble classifier (R=0.36, p=3.4×10<sup>-8</sup>, Figure 6D) which highlights an important 639 link between the purely clinical variables recorded for this cohort and the PDAC signature. Most 640 importantly, the stacked index succeeded in attributing higher odds ratios above 1 to several PDAC 641 cases that would have otherwise escaped detection had a QCancer score above 3 been taken as the

risk predictor (Figure 6D). Contrarily, when depending exclusively on the QCancer score, and using it to calculate the ROC AUC, the predictive capacity for PDAC in the ADEPTS samples is noticeably diminished in comparison to the performance of the ensemble index (Figure 6B); this was verified in all samples with a Qcancer score ( $p=1.56\times10^{-18}$ , one-sided bootstrap test comparing AUCs), with a score above 2 ( $p=1.24\times10^{-10}$ ), above 2.5 ( $p=3.68\times10^{-13}$ ) and above 3 ( $p=2.33\times10^{-8}$ ). This justifies the PDAC signature as a useful complementary resource for enhanced and accelerated diagnosis in the clinic.

648

## 649 **Discussion**

650

651 Our objective was to construct a multi-biomarker signature that could effectively differentiate individuals 652 with non-specific yet concerning symptoms attributable to both benign abdominal pathologies and 653 PDAC. CA19-9 tumour marker blood levels are used clinically to help confirm PDAC diagnosis in a 654 clinical context (positive findings on imaging, histopathology), prognosticate and monitor recurrence 655 following tumour resections (58). Its absent expression in Lewis body negative blood group individuals, 656 an overall limited predictive capacity (79-81% test sensitivity and 82-90% specificity at best) and 657 especially in the presence of certain inflammatory pancreatico-biliary conditions, have driven 658 researchers to rather combine it in multi-marker panels to enhance its predictive performance (29, 30, 659 58). In an evolving multi-omics area, reported panels have included proteins, circulating nucleic acids 660 (micro-RNA, cfDNA) or tumours cells, metabolites, and products of alternative DNA splicing and 661 methylations (58, 59), developed to differentiate PDAC from healthy and those with benign pathologies. 662 Yet, the role of such diagnostic and screening panels in symptomatic cohorts remains unestablished.

663

664 The sampled population in our study is an enriched, symptomatic, secondary care cohort where the 665 prevalence of PDAC was close to 8%, representing figures observed in our hepatobiliary specialised 666 referral centres. By using this target population and their unique set of serum samples provided by the 667 ADEPTS study (33), we were able to develop a biomarker signature in a cohort of patients who were 668 referred to our participating centres (University College London Hospitals, London UK and the Royal 669 Free Hospital, London UK) with various abdominal and hepatobiliary conditions which in symptomatic 670 presentation might overlap with PDAC (20). Moreover, we included samples from patients with known 671 risk factors for PC (chronic pancreatitis, those with family history of PDAC and cystic lesions of the

pancreas, CLPs) and with biliary conditions that are known confounders of CA19-9 (i.e. biliary tract
inflammation/obstruction, pancreatitis, CLPs) - the only tumour marker clinically applied in the workup
and management (29, 39, 60) of PDAC.

675

676 We employed ensemble methods, which have achieved impressive accuracy in numerous complex 677 classification tasks (36, 42, 43, 61). Specifically, we utilized stacking—a form of meta-learning (43)—to 678 create a superior-level predictive model based on the predictions of diagnostic-specific base classifiers. 679 These classifiers leveraged a diverse set of features, highlighting the fundamental importance of 680 heterogeneity arising from specific diagnoses when compared against PDAC, an approach previously 681 demonstrated to be effective (36, 42). Moreover, this study enabled us to evaluate the specificity of our 682 early detection machine learning approach (36) within a relevant symptomatic population, thereby 683 allowing us to address confounding factors that may impact their performance. The use of such 684 diagnostic specialized base-learners was further justified by the data asymmetry between PDAC cases 685 and controls observed in both the discovery and validation datasets.

686

687 Across all diagnosis classes (base learners) the index signature which comprised 44 clinical and serum 688 protein covariates predicted PDAC (all stages) with an AUC of 0.98 (95% Cl 0.98 - 0.99); at 90% 689 specificity, a sensitivity of 0.99 (95% CI 0.98 - 1), PPV 0.92 (95% CI 0.91 - 0.92) and NPV 0.99 (95% 690 CI 0.97 - 1) was reached, in contrast to CA19-9 as a single predictor under a logistic regression model 691 - AUC 0.79 (95% CI 0.66 - 0.91), sensitivity 0.67 (95% CI 0.50 - 0.83), PPV 0.32 (95% CI 0.26 - 0.38) 692 and NPV of 0.97 (95% CI 0.96 - 0.99). On validation, an AUC of 0.95 (95% CI 0.91 - 0.99), sensitivity 693 0.86 (95% CI 0.68 - 1), PPV 0.54 (95% CI 0.48 - 0.58) and NPV of 0.98 (95% CI 0.95 - 1) was achieved 694 by the signature, compared to an AUC of 0.80 (95% CI 0.66 - 0.93), sensitivity 0.65 (95% CI 0.48 -695 0.56), PPV 0.49 (95% CI 0.41 - 0.56) and NPV of 0.95 (95% CI 0.92 - 0.98), for CA19-9.

696

The performance of this index panel must be appreciated within the context of the complex biology associated with each of the ensembled diagnostic classes, i.e., the challenges associated with biomarker alterations on the background of pancreatico-biliary inflammatory and obstructive pathologies. When applying a redacted, 8-marker signature (CA19-9, VWF, CPE, CTSV, CEACAM1,CD160, Diabetes and Age) - features that were selected with relatively high importance

702 across most base learners, the performance was naturally reduced, yet still performed significantly 703 better against CA19-9 as a single marker during discovery. Using the general linear model stack as 704 was done in the case of the full index, the reduced signature predicted PDAC with AUC of 0.97 (95% 705 CI 0.95-0.98), sensitivity 0.98 (95% CI 0.95-1), PPV 0.92 (95% CI 0.91-0.92) and NPV of 0.98 (95% CI 706 0.94-1), at 90% specificity (Supplementary Figure 4C), values comparable to the full index. During 707 validation, however, the predictive capacity of the reduced signature was significantly reduced 708 compared to the full stacked model (Supplementary Figure 4D) and only marginally superior to CA19-709 9 alone across the cohort. In contrast, it still outperformed CA19-9 by a significant margin when 710 predicting PDAC against healthy controls.

711

712 As validation of its performance, we also applied the full index signature to the cohort, which were re-713 stratified based on presenting symptoms in contrast to the ensemble of classifiers which were 714 developed independently of symptomatic data and with no further model refinement. The aim was to 715 test the signature performance in differentiating PDAC cases from controls by accounting for presenting 716 symptoms, and which have been linked with repeated primary care consultations up to two-years prior 717 to PDAC diagnosis (20) (Figure 4). Enriched by fulfilling certain sociodemographic, clinical and 718 attributable suspicious symptom (identified using CDSTs such as QCancer tool), symptomatic patients 719 would form an ideal cohort for further risk stratification by minimally invasive blood biomarker testing for 720 prioritisation of more invasive (and costly) investigations. Yet, contrary to the full index, in the cohort 721 used in the current work the QCancer score used as the sole predictor of PDAC did not achieve 722 significant performances in samples above the threshold of 3%. This further motivates the recourse to 723 combined strategies where complementary biomarker panels such as those identified by ensemble 724 modelling approaches could improve early detection when used in conjunction with CDSTs.

725

726 In our test subjects, however, only 'Jaundice' ( $p=3.22\times10^{-15}$ ), and 'Weight Loss' ( $p=1.44\times10^{-6}$ ) were 727 significantly associated with PDAC. When testing the diagnostic performance of the full index signature 728 in all symptomatic patients presenting with 'Weight Loss', the signature significantly outperformed 729 CA19-9: AUC<sub>signature</sub> of 0.95 (95% CI 0.90 - 0.1) vs. AUC<sub>CA19-9</sub> of 0.74 (95% CI 0.58 - 0.90) (Figure 5A, 730 Table 2 and Supplementary Table 11). 'Weight loss' has previously been reported to have the longest 731 diagnostic interval in a prospective primary cohort study (SYMPTOM pancreatic study), assessing

symptom trends and associated diagnostic intervals in PC (14). Attesting to the full index signature's capacity as a rule out test in such patients, is its outstanding negative predictive value compared to that of CA19-9 (0.97 95% CI 0.75-1 vs. 0.81 95% CI 0.73-0.9, respectively) (Table 2). Similarly, the index signature performed superiorly to CA19-9 in jaundiced patients (AUC of 0.89 (95% CI 0.79 - 0.99) vs. CA19-9 AUC of 0.70 (95% CI 0.53 - 0.86), see also Supplementary Table 11), which underscores once again the increased capacity of the ensemble index to better identify PDAC in the presence of a known confounder of CA19-9 (29, 39).

739

740 While our study provides valuable insights, it is not without limitations. While the observed prevalence 741 of PDAC in this study aligns with secondary care population trends, enhanced specificity and positive 742 predictive value would necessitate larger cohorts with an increased number of cases. Moreover, the 743 sample set representing the 'Healthy' control class warrants expansion to incorporate a more diverse 744 population of both men and women. This control class, derived from the UKCTOCS samples used in a 745 previous study (36), exclusively comprised women. Given its superior performance in predicting PDAC, 746 as depicted in Figure 2, the inclusion of male samples within this class could further enhance the breadth 747 of the panel of markers identified in this study. Lastly, although diabetes emerged both as a risk factor 748 and a central clinical covariate in our signature (including in the reduced panel), we must emphasize 749 and recognise the lack of complete (type, duration) data in the UKCTOCS cohort (36). Nevertheless, 750 diabetes mellitus (and in particularly of new onset) is an established risk factor and therefore its inclusion 751 as a relevant feature in the signature is of no surprise (9).

752

While both our index and reduced signature were superior to CA19-9 in their predictive performance and compensated for asymmetric binary classes by creating a diagnostic-specific ensemble, its complexity challenges its utilisation in clinic. Yet, in the current era of rapidly evolving assay technologies, the utilization of a complex biomarker signature comprising numerous variables has gained significant relevance. While the complexity of these biomarker signatures may pose analytical challenges, the evolving assay technologies offer the means to effectively harness their potential.

759

Future enhancements however, will naturally necessitate the study of larger cohorts, potentially incorporating a biomarker-contextualized machine learning perspective that accounts for samplespecific aspects related to diagnosis, a strategy employed in other cancer research domains (62). The

utilization of disease trajectory tracking and clinical history analysis (63) may also facilitate the application of advanced deep learning techniques and electronic health data. When combined with ensemble biomarker signatures taken for example in a longitudinal context (36, 64), these approaches could enhance the estimation of PDAC risk within an enriched symptomatic population.

767

768 **Data Availability**: Data requestors will need to sign a data access agreement and in keeping with 769 patient consent for secondary use obtain ethical approval for any new analyses.

770

771 Acknowledgments: We thank the participants of the ADEPTS study and UKCTOCS trial, the 772 management team, research nurses, interviewers, research assistants, and other staff who gathered 773 the data that was used in this work. This research was funded by Cancer Research UK (grant 774 C12077/A26223) and supported by the Pancreatic Cancer UK Early Diagnosis Award 2018, project 775 "The Accelerated Diagnosis of neuroEndocrine and Pancreatic TumourS (ADEPTS)" (IRAS Number: 776 234637, NIHR Portfolio no. 7343), and by the National Institute for Health Research (NIHR) University 777 College London Hospitals Biomedical Research Centre. UKCTOCS was core funded by the Medical 778 Research Council, Cancer Research UK, and the Department of Health with additional support from 779 the Eve Appeal, Special Trustees of Bart's and the London, and Special Trustees of University College 780 London Hospitals. EC is supported by Cancer Research UK (C7690/A26881). UM acknowledges MRC 781 Core funding (MC UU 00004/01). SPP is supported by Cancer Research UK Early Detection and 782 Diagnosis Programme EDDPGM-May22\100002 (CANDETECT, Co-PI Prof Fiona Walter).

783

Author contributions: AN, NRN, SPP, UM and AZ conceived the study. SPP, AZ and UM secured funding. NRN constructed the models, performed the statistical analysis and produced the figures. AN and NRN interpreted the data in collaboration with SPP and AZ. AN, NRN, SPP and AZ drafted the paper. ES and AN performed the experiments for all in-house biomarkers. All authors contributed to data acquisition and interpretation, and critically reviewed and approved the article:

AN, NRN, ES, PA, OB, HJW, EC, AGM, NRW, UM, GKF, AZ, SPP.

790

791 **Competing interests**: The authors declare the following competing interests: UM reports stock 792 ownership in Abcodia UK between 2011 and 2021; UM has received grants from the Medical Research

Council (MRC), Cancer Research UK, the National Institute for Health Research (NIHR), the India Alliance, NIHR Biomedical Research Centre at University College London Hospital, and The Eve Appeal; UM currently has research collaborations with iLOF, RNA Guardian and Micronoma, with funding paid to UCL; UM holds patent number EP10178345.4 for Breast Cancer Diagnostics; AG currently has research collaborations with Micronoma and iLoF, with the research funding awarded to UCL. No other potential conflicts of interest were disclosed by any of the authors. 

medRxiv preprint doi: https://doi.org/10.1101/2023.12.24.23300505; this version posted December 28, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

### 813

#### 814 Tables:

815 816 817 818 819 Table 1. Cohort characteristics. The data set used to develop and test the classifiers is a combination of samples collected from ADEPTS cohort and selected controls from the UKCTOCS cohort. BMI: Body Mass Index. See Study Design in Materials and Methods section for additional details. Odds ratio (OR) and respective 95% confidence intervals are also provided in the p value column.

Variable	Cases	Controls	p value
ADEPTS			
No. samples	46	421	
Stage I Stage II Stage III Stage IV Unknown	4 15 10 16 1	- - - -	-
Mean age at sample draw (yr) (range)	69.72 (43.00-91.00)	57.44 (19.00-93.00)	2.47×10 <sup>-7</sup> OR= 1.06 (1.04 – 1.09)
Mean BMI (kg/m2) (range)	24.84 (12.04-41.35)	25.30 (15.22-39.45)	0.47 OR=0.97 (0.88 – 1.06)
Gender	31	180	
Female	15	241	0.0015 OR=2.72 (1.46 – 5.27)
Diabetes			
Yes	10 (8Type II, 1 Type I, 1 unspecified)	75 (34 Type II, 41 unspecified)	0.44 OR=1.34 (0.62 – 2.70)
No	36	346	
Ethnicity	04	204	
Caucasian	21	291	
Unknown	21	60	6.56×10 <sup>-4</sup>
Asian	3	30	OR=2.02 (1.34 – 3.03)
Other Afro/Caribbean	2 0	18 22	
UKCTOCS			
No. samples	-	72	-

Mean age at sample draw (yr) (range)	-	62.95 (50.44-76.86)	-
Mean BMI (kg/m2) (range)	-	26.53 (17.91-42.19)	-
Gender			
Male	-	-	-
Female	-	72	
Diabetes			
Yes	-	3 (3 Type II)	-
No	-	69	
Ethnicity			
Unknown	0	72	-

<sup>820</sup> 821 822

823 824 825 826 827 828 Table 2 Performance summary for selected models in symptomatic patients. The probability values used to calculate the performance metrics were generated with each model developed in the training set and reported in the main text. Probability values for symptomatic patients belonging to the training set and validation set were concatenated to generate the ROC curves. Only ADEPTS samples had symptoms information. A. L. Derang .: Asymptomatic LFT Derangement. B. Pain: Back Pain. C. B. Habit: Change in Bowel Habit. W. Loss: Weight Loss. 95% confidence intervals are provided in parentheses. See also Supplementary Table 10 for the explicit 829 performance ranks according to model, symptom and metric and Figure 5.

				Symptom (Yes)		
Models	Metric	A.L.Derang.	A. Pain	A. B. Habit	W.Loss	Jaundice
	ROC	0.85 (0.62-1)	0.81 (0.65-0.96)	0.82 (0.57-1)	0.74 (0.58-0.90)	0.70 (0.53-0.86)
CA 10.0	Sens90	0.75 (0.38-1)	0.69 (0.44-0.94)	0.71 (0.42-1)	0.53 (0.24-0.76)	0.41 (0.14-0.73)
CA19-9	PPV90	0.54 (0.37-0.61)	0.36 (0.26-0.43)	0.46 (0.34-0.55)	0.70 (0.50-0.77)	0.83 (0.64-0.90)
	NPV90	0.96 (0.90-1)	0.97 (0.95-0.99)	0.96 (0.93-1)	0.81 (0.73-0.90)	0.55 (0.46-0.73)
	ROC	0.98 (0.95-1)	0.98 (0.97-1)	0.97 (0.92-1)	0.95 (0.90-1)	0.89 (0.79-0.99)
Index	Sens90	1 (0.62-1)	0.94 (0.81-1)	0.86 (0.56-1)	0.94 (0.29-1)	0.73 (0.36-0.91)
signature	PPV90	0.61 (0.49-0.61)	0.43 (0.40-0.45)	0.51 (0.41-0.55)	0.8 (0.56-0.81)	0.90 (0.82-0.92)
	NPV90	1 (0.94-1)	0.99 (0.98-1)	0.98 (0.95-1)	0.97 (0.75-1)	0.73 (0.54-0.89)
	ROC	0.97 (0.93-1)	0.92 (0.88-0.99)	0.91 (0.83-0.98)	0.92 (0.85-0.99)	0.82 (0.67-0.97)
Reduced	Sens90	1 (0.63-1)	0.81 (0.38-1)	0.57 (0.14-1)	0.71 (0.35-0.94)	0.77 (0-0.95)
signature	PPV90	0.61 (0.49-0.94)	0.40 (0.23-0.45)	0.41 (0.15-0.55)	0.75 (0.6-0.8)	0.90 (0-0.92)
	NPV90	1(0.94-1)	0.98 (0.95-1)	0.95 (0.9-1)	0.88 (0.76-0.97)	0.76 (0.42-0.94)

medRxiv preprint doi: https://doi.org/10.1101/2023.12.24.23300505; this version posted December 28, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in percetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

- 831
- 832
- 833 Figures:

834

835 Figure 1 Characteristics of the discovery and validation sets. Number of controls across the discovery and 835 836 837 838 839 840 841 validation sets (A), number of PDAC cases per stage (B), and association of BMI, Age, Diabetes, Ethnicity and Gender with PDAC status (C-F). In C, D, E and F dot sizes correspond to odds ratios and are colour coded according to their respective values, i.e., blue if OR<1 and red if OR>1. p values were calculated according to a logistic regression model with a bias reduction method. Purple dashed lines correspond to -Log[0.05]. G Receiver Operating Curve (ROC) Area Under the Curve (AUC), Sensitivity (Sens), Positive Predictive Value (PPV) and Negative Predictive Value (NPV) at 90% Specificity (Spec) performance of single marker models, i.e. BMI and Age, 842 843 in the validation set. H Similar to A but for Gender, Ethnicity and Diabetes. Performances were calculated with the respective single feature models developed in the discovery set. The ROC AUC significance threshold is also 844 represented by a purple dashed line at 0.5. Error bars in figures corresponding to the validation set are the 95% 845 Confidence Intervals (CI), calculated by stratified bootstrapping 2000 times. See Statistical Analysis in Methods 846 (main text) for further details and Supplementary Table 6, 7 and 8.



medRxiv preprint doi: https://doi.org/10.1101/2023.12.24.23300505; this version posted December 28, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

858 Figure 2 Performance of individual base-learner classifiers, stack ensemble and state-of-the art algorithms. 859 A Base-learners performance in the discovery set. Each base-learner classifier was developed by training with a 860 recursive feature elimination technique (RFE) and logistic regression (glm) in samples belonging to each specific 861 diagnosis class against the same 24 PDACs in the discovery set. The performance reported in A is, nevertheless, 862 of each classifier in the whole discovery set. The performances reported in B correspond to the base-learners 863 developed in the discovery set but applied to the whole validation set. In C and D the performance of the ensemble 864 stack based on the base-learners presented in A and B, as well as of state-of-the-art algorithms (xgbTree, RRF 865 and RFE glm) is reported in the discovery and validation sets, respectively. xgbTree, RRF and RFE glm were 866 trained in the whole discovery set, which contrasts with the ensemble algorithm.



medRxiv preprint doi: https://doi.org/10.1101/2023.12.24.23300505; this version posted December 28, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

### 

Figure 3 Features selected per diagnosis class (base-learner classifiers). The scaled importance is calculated within each base-learner (Figure 2A). Selected features are ranked from left to right according to the average scaled importance across base learners. See Figure 1, Supplementary Figure 1 and Supplementary Tables 3 and for the univariate predictive performances of each of the markers in the discovery and validation sets. See Methods section for details on model-agnostic algorithm for feature importance calculation.



medRxiv preprint doi: https://doi.org/10.1101/2023.12.24.23300505; this version posted December 28, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



Figure 4 Association between symptoms and PDAC. A Number of subjects with each symptom according to PDAC status, case or control. B Association of symptoms with PDAC status, p values were calculated according to a logistic regression model with a bias reduction method. Purple dashed lines correspond to -Log [0.05]. In B dot sizes correspond to odds ratios and are colour coded according to their respective values, i.e., blue if OR<1 895 and red if OR>1. See also Supplementary Table 9. Only samples belonging to the ADEPS cohort were used as no 896 information about symptoms was available for the UKCTOCS set of samples.



- 899
- 900



901 902

903

904

905

906 907

908

909

910 911

912 913





Figure 5 Receiver operating curves for selected models in symptomatic patients. A Only CA19-9. B Full

index signature. C Reduced index signature. The probability values used to calculate the performance metrics were

generated with each model developed in the discovery set and reported in the main text. Probability values for

symptomatic patients belonging to the discovery set and validation set were concatenated to generate the ROC

curves. Only ADEPTS samples had symptoms information. A. L. Derang.: Asymptomatic LFT Derangement. B.

medRxiv preprint doi: https://doi.org/10.1101/2023.12.24.23300505; this version posted December 28, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in percetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

914 915

Figure 6 Prediction of PDAC in patients with specific symptoms and according to QCancer score values. The ensemble stack was selected as the best model according to Figure 2. A Performance of the stack in participants for which a Qscore had been calculated or above a specific threshold, bigger than 2, 2.5 or 3.0. B Performance of the Qscore taken as the predictor of PDAC risk in participants for which a Qscore had been calculated or above a specific threshold, bigger than 2, 2.5 or 3.0. C Number of subjects that had a calculated Qscore or are above a specific threshold, bigger than 2, 2.5 or 3.0. D Correlation between QCancer score and odds ratio of PDAC according to the stacked ensemble. E is in log scale. The QCancer score is identified as Qscore in the figure panels.

924



925 926

# 927 Supplementary Information

### 928 Title: Identification of a serum proteomic biomarker panel using diagnosis specific ensemble 929 learning and symptoms for early pancreatic cancer detection

### 930 Authors:

- Alexander Ney<sup>1,\*</sup>, Nuno R. Nené<sup>2,3,4\*</sup>, Eva Sedlak<sup>2</sup>, Pilar Acedo<sup>1</sup>, Oleg Blyuss<sup>2,5,6</sup>, Harry J. Whitwell<sup>2,7,8</sup>,
  Eithne Costello<sup>9</sup>, Aleksandra Gentry-Maharaj<sup>2,10</sup>, Norman R. Williams<sup>11</sup>, Usha Menon<sup>10</sup>, Giuseppe K.
  Fusai<sup>12</sup>, Alexey Zaikin<sup>2,13,14</sup>, Stephen P. Pereira<sup>1,\*</sup>.
- 934

### 935 Affiliations:

936

<sup>1</sup> Institute for Liver and Digestive Health, University College London, Upper 3<sup>rd</sup> Floor, Royal Free
 Campus, Rowland Hill Street, London NW3 2PF, United Kingdom

<sup>2</sup> Department of Women's Cancer, EGA Institute for Women's Health, University College London, 84 86 Chenies Mews, London, WC1E 6HU, United Kingdom

<sup>3</sup>Cancer Institute, University College London, 72 Huntley St, London, WC1E 6DD, United Kingdom.

945 946 947	4 1-19	Department Torrington Pla	of ace, London	Statistical , WC1E 6BT, U	Science, Jnited Kingdom	University	College	London			
948 949 950	<sup>5</sup> Wolfson Institute of Population Health, Queen Mary University of London, Charterhouse Square, EC1M 6BQ, London, United Kingdom										
950 951 952	<sup>6</sup> Dep Mosc	partment of Percow State Med	diatrics and lical Univers	Pediatric Infec ity (Sechenov	tious Diseases, l University), Mos	nstitute of Child cow, Russia	's Health, Sech	enov First			
953 954	<sup>7</sup> Nat Diges	tional Phenom stion and Repr	ne Centre a roduction, IF	nd Imperial C RDB, Building I	linical Phenotyp mperial College	ing Centre, De <sub>l</sub> London, W12 O	partment of Me NN, United King	etabolism, gdom			
955 956 957	<sup>8</sup> Seo Diges Unite	ction of Bioar stion and Rep ed Kingdom	nalytical Ch production,	emistry, Divis Sir Alexander	ion of Systems Fleming Buildin	Medicine, Dep g, Imperial Coll	ege London, S	etabolism, ₩7 2AZ,			
958 959 960 961	<sup>9</sup> De Kingo	partment of N dom	lolecular an	d Clinical Car	ncer Medicine, l	Jniversity of Liv	erpool, Liverpoo	ol, United			
962 963 964	<sup>10</sup> MF Lond	RC Clinical Tr lon, 90 High H	ials Unit at olborn, 2nd	UCL, Institute Floor, London,	of Clinical Tria WC1V 6LJ, Uni	ls and Methodo ited Kingdom	ology, Universit	y College			
965	<sup>11</sup> Div	vision of Surge	ery & Interve	entional Scienc	e, University Col	llege London, Lo	ondon, United K	ingdom			
966 967 968	<sup>12</sup> HP	B & Liver Trar	nsplant Unit	, Royal Free Lo	ondon, London N	IW3 2QG, Unite	d Kingdom				
968 969	<sup>13</sup> Ins	stitute for Cogr	nitive Neuro	science, Unive	rsity Higher Sch	ool of Economic	s, Moscow, Rus	sia			
970 971 972	<sup>14</sup> De	epartment of M	athematics,	University Col	lege London, Lo	ndon WC1H 0A	Y, United Kingo	lom			
973 974	* The	ese authors co	ntributed ec	ually to the wo	ork						
975	To w	hom correspo	ndence sho	uld be address	ed:						
976	Dr A	lexander Ney	(Email: <u>alex</u>	ander.ney.15@	<u>@ucl.ac.uk</u> )						
977	Dr N	luno Rocha Ne	ené (Email:	nuno.nene.10(	@ucl.ac.uk )						
978	Prof	Stephen Pere	eira (Email: s	stephen.pereira	a@ucl.ac.uk)						
979 980 981											
982 983											
984											
985	In thi	s supplementa	ary informati	on we provide	the additional ta	bles and figures	cited in the ma	in text.			
986											
987											
988											

medRxiv preprint doi: https://doi.org/10.1101/2023.12.24.23300505; this version posted December 28, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

#### 989

## 990 Supplementary Figures

### 991

992 Supplementary Figure 1 Biomarker ranks in the discovery set. A Distribution and ranks of biomarkers by p 993 values in the discovery set. Purple dashed line corresponds to -Log [0.05]. B Receiver Operating Curve (ROC) 994 Area Under the Curve (AUC), Sensitivity (Sens), Positive Predictive Value (PPV) and Negative Predictive Value 995 (NPV) at 90% Specificity (Spec) performance of single marker models in the validation set set. OR stands for odds-996 997 ratio, with dot size proportional to the calculated values. Red and blue OR points represent OR > 1 (favours pancreatic ductal adenocarcinoma (PDAC) case status) and OR < 1 (favours Control status), respectively. p values 998 were calculated according to a logistic regression model with a bias reduction method. Performances were 999 calculated with the single feature models developed in the discovery set. The ROC AUC significance threshold is 1000 also represented by a purple dashed line at 0.5. Error bars in figures corresponding to the validation set correspond 1001 to 95% Confidence Intervals (CI), calculated by stratified bootstrapping 2000 times. See statistical analysis section 1002 in Methods (main text) for further details and Supplementary Table 3 and 4.

1003



- 1004 1005
- 1005

1007 Supplementary Figure 2 Flow diagram for the stack ensemble classifier. The general linear stack model 1008 presented in the main text was built according to this diagram, where base-learners are trained in groups of control 1009 samples with a specific diagnosis and the same PDAC cases. The stacking procedure has 2 steps. First, the 1010 probability output vectors for each base-learner are concatenated, thus leading to n probability vectors, where n is 1011 the number of diagnosis subclasses. Second, these vectors are subsequently used to populate the diagonal blocks 1012 1013 of a large probability matrix. The off-diagonal probability blocks are generated by using the base models trained in a specific diagnosis subclass plus the same PDACs, which therefore amounts to computing cross diagnosis 1014 predictions. The resulting large matrix has n columns and is then used to train the meta-learner which outputs the 1015 final probability vector. For the purposes of applying the resulting trained models to the validation set, the flow of 1016 the diagram is the same as before, but the feature matrix will have a different number of samples.



**Diagnosis Ensemble Stack** 

1019									
1020									
1020									
1021									
1022									
1022									
1023									
1024	ensemble. A	Kyoto Encyclopaedia of Gene	ilysis. g:Profil es and Genon	er terms for the nes (KEGG) pa	e set of feat athways. <b>C</b>	ures select Reactome	ed by the ful Pathway Da	l stack tabase	
1026 1027 1028	(REAC). <b>E</b> V values asso Statistical Ar A	VikiPathways (WP). <b>G</b> Gene or ciated with each enrichment te nalysis in Methods for further de	ntology terms rm or pathwa etails.	biological proc y are plotted in	ess (GO: B n <b>B</b> , <b>D</b> , <b>F</b> a	P). The res nd <b>H</b> . See B	pective adjus also Figure	sted p- 3. See	
1026 1027 1028	(REAC). E V values asso Statistical Ar A	VikiPathways (WP). <b>G</b> Gene or ciated with each enrichment te nalysis in Methods for further de	ntology terms erm or pathwa etails.	biological proc y are plotted in Protein Biomarke	ess (GO: B n <b>B</b> , <b>D</b> , <b>F</b> a	P). The res nd <b>H</b> . See B	pective adju also Figure ₋∟	sted p- 3. See og [P value]	
1026 1027 1028	(REAC). E V values asso Statistical Ar A	VikiPathways (WP). <b>G</b> Gene or ciated with each enrichment te nalysis in Methods for further de	ntology terms erm or pathwa etails.	biological proc y are plotted in Protein Biomarke	ess (GO: B n <b>B</b> , <b>D</b> , <b>F</b> a	P). The res nd <b>H</b> . See B	pective adjus also Figure -L	sted p- 3. See og [P value]	15
1026 1027 1028	(REAC). E V values asso Statistical Ar A	VikiPathways (WP). <b>G</b> Gene or ciated with each enrichment te nalysis in Methods for further de	ntology terms erm or pathwa etails.	biological proc y are plotted in Protein Biomarke	ess (GO: B n <b>B</b> , <b>D</b> , F a	P). The res nd H. See B	pective adjus also Figure -L	sted p- 3. See og [P value]	15
1026 1027 1028	(REAC). E V values asso Statistical Ar A	VikiPathways (WP). G Gene or ciated with each enrichment te nalysis in Methods for further de PBK-AKT SIGNALING PATHWAY	ntology terms erm or pathwa etails.	biological proc y are plotted in Protein Biomarke	ess (GO: B n <b>B</b> , <b>D</b> , F a ***	P). The res nd H. See B	pective adjus also Figure -L	sted p- 3. See og [P value]	15
1026 1027 1028	(REAC). E V values asso Statistical Ar A	VikiPathways (WP). G Gene or ciated with each enrichment te halysis in Methods for further de PISK-ART SIGNALING PATHWAY ERBB SIGNALING PATHWAY PATHWAYS IN CANCER	ntology terms erm or pathwa etails.	biological proc y are plotted in Protein Biomarke	ess (GO: B n <b>B</b> , <b>D</b> , <b>F</b> a 	P). The res nd H. See B	pective adjus also Figure -L	sted p- 3. See og [P value]	15
1026 1027 1028	(REAC). E V values asso Statistical Ar A	VikiPathways (WP). G Gene or ciated with each enrichment te halysis in Methods for further de PBK-AKT SIGMALING PATHWAY ERBS SIGMALING PATHWAY HUMAN PARILOMWARDS IN CANCER HUMAN PARILOMWARDS IN CONCER	ntology terms frm or pathwa etails.	biological proc y are plotted in Protein Biomarke	ess (GO: B n <b>B</b> , <b>D</b> , <b>F</b> a	P). The res nd H. See B	pective adjus also Figure -L 5.03 4.67 3.415	sted p- 3. See og [P value]	15
1026 1027 1028	(REAC). E V values asso Statistical Ar A	VikiPathways (WP). G Gene or ciated with each enrichment te halysis in Methods for further de PISK-AKT SIGNALING PATHWAY ERBB SIGNALING PATHWAY PATHWAYS BIONALING PATHWAY PATHWAYS IN PATHWAYS IN FRECTION PROTEOGLYCANS IN CANCER HUMAN PAPILLOWARRUS INFECTION	ntology terms erm or pathwa etails.	biological proc y are plotted in Protein Biomarke	ess (GO: B n <b>B</b> , <b>D</b> , <b>F</b> a	P). The res nd H. See B	pective adjus also Figure 5 5 5 5 5 5 5 5 5 3 4 67 3.41 8.15 2.42 2.19	sted p- 3. See og (P value)	15
1026 1027 1028	(REAC). E V values asso Statistical A A	VikiPathways (WP). G Gene or ciated with each enrichment te nalysis in Methods for further de PISK-AKT SIGNALING PATHWAY ERBB SIGNALING PATHWAY HUMAN PAPILCOMVIS IN FECTION PROTEOGLYCANS IN CANCER PLATHUM DRUG RESISTANCE PLATHUM DRUG RESISTANCE	ntology terms erm or pathwa etails.	biological proc y are plotted in Protein Biomarke	ess (GO: B n <b>B</b> , <b>D</b> , <b>F</b> a	P). The res nd H. See B	pective adjus also Figure -L 5.03 4.67 3.41 2.42 2.19 1.69	sted p- 3. See og [P value]	15
1026 1027 1028	(REAC). E V values asso Statistical Ar A	VikiPathways (WP). G Gene or ciated with each enrichment te nalysis in Methods for further de PISK-ART SIGNALING PATHWAY ERB SIGNALING PATHWAY PATHWAYS IN CANCER HUMAN PAPHILOMAYRUS INFECTION PROTEOG VOLUME IN CANCER PLATINUM DRUG RESISTANCE PROTEOG VOLUME IN CANCER PROTEIGE VALUES	ntology terms erm or pathwa etails.	biological proc y are plotted in Protein Biomarke	ess (GO: B n <b>B</b> , <b>D</b> , <b>F</b> a	P). The res nd H. See B	pective adjus also Figure -L 5:03 4:67 3:41 3:45 2:49 1:69 1:69	og [P value]	15
1026 1027 1028	(REAC). E V values asso Statistical Ar A	VikiPathways (WP). G Gene or ciated with each enrichment te halysis in Methods for further de PISKART SIGNALING PATHWAY ERB SIGNALING PATHWAY HUMAN FARILOMAVIRUS INCOMCER HUMAN FARILOMAVIRUS IN CANCER PROTEOQUEANS IN CANCER PROSTATE CANCER TYPE I DIABETES MELITUS BLADDER CANCER	ntology terms frm or pathwa etails.	biological proc y are plotted in Protein Biomarke	ess (GO: B n <b>B</b> , <b>D</b> , <b>F</b> a	P). The res nd H. See B	pective adjus also Figure -L 5.03 4.67 3.41 8.15 2.42 2.19 1.69 1.66 1.63	og [P value]	15
1026 1027 1028	(REAC). E V values asso Statistical Ar A	VikiPathways (WP). G Gene or ciated with each enrichment te halysis in Methods for further de PISK-AKT SIGNALING PATHWAY ERB SIGNALING PATHWAY PATHWAY SI CANCER HUMAN PAPILLOMAVIRUS INFECTION PROTOCI YOMS IN CANCER PLATINUM ORD RESISTANCE PROSTATE CANCER TYPE I DURBETES MELITUS BLADDER CANCER CYTOKINE CYTOKINE RECEPTOR INTERACTION	ntology terms frm or pathwa etails.	biological proc y are plotted in Protein Biomarke	ess (GO: B n <b>B</b> , <b>D</b> , <b>F</b> a	P). The res nd H. See B	5 5 5 3.467 3.41 3.15 2.29 1.69 1.66 1.63 1.57	sted p- 3. See og [P value]	15

	FOCAL ADHESION XX X X	1.45
С	D	
	STANDE EVERT	0 5 10 15
c	PLC91 EVENTS IN ERBB2 SIGNALING     X	1.67
RFA		1.45
	TNFS BIND THEIR PHYSIOLOGICAL RECEPTORS X X X	1.41
Е	F	
	CEBRICHER STADDER STADD	0 5 10 15
	ERBB SIGNALING PATHWAY X X X X X	3.90
đ	SARS-COV-2 INNATE IMMUNITY EVASION AND CELL-SPECIFIC IMMUNE RESPONSE X X X X X X	1.87
5	S PI3K-AKT SIGNALING PATHWAY X X X X X X X X	1.54
	MAMMARY GLAND DEVELOPMENT PATHWAY - PREGNANCY AND LACTATION (STAGE 3 OF 4) X X	1.49
G	H	

		CORPORATION OF	L'ALLE			Selete	072 port		Clert &	2000	CH COM		CR POR	NO TOTAL STRUCTO	0	5	10	15
	CIRCULATORY SYSTEM DEVELOPMENT	- ×××	< ×	×	××	××		××>	<××		×	×××××	×	××		_	_	15.3
	BLOOD VESSEL MORPHOGENESIS	- ×××	< ×	×	×	×		××	××		×	× ×××	×	××				14.8
	CELL ADHESION	×× ×	<××	××	××:	× :	×	×	×	×	×	×× ××	××:	××× ×		_	_	14.8
	ANGIOGENESIS	$\times \times \times$	< ×	×		×		$\times \times$	XX		×	× ×××	×	××				14.6
	BLOOD VESSEL DEVELOPMENT	$\times \times \times$	$\langle \times \rangle$	×	×	×		$\times \times$	××		×	$\times$ $\times \times \times$	×	××				13.8
	TUBE MORPHOGENESIS	$\times \times \times$	< ×	×	×	×	×	$\times \times$	××		×	× ×××	×	××				13.5
5	VASCULATURE DEVELOPMENT	$\times \times \times$	< ×	×	×	×		$\times \times$	××		×	× ×××	×	××				13.4
ä	TUBE DEVELOPMENT	- ×××	< ×	×	×	×	×	$\times \times$	××		×	×× ×××	×	××				12.9
ğ	ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS	$\times \times \times$	$\langle \times \rangle$	×	×	×	××	$\times \times$	××		×	× ×××	×	××			11	2.3
	REGULATION OF CELL ADHESION	×× ×	$\langle \times \rangle$	×	X	X	×	×	×	×	×	×× ××	×	×			11.6	3
	POSITIVE REGULATION OF CELL POPULATION PROLIFERATION	$\times \times \times$	< ×		X	×××	×	$\times \times$	×	×		$\times$ $\times$ $\times$	×	×			10.1	
	CELL-CELL ADHESION	××	×	××	;	X :	×	×	×	×	×	×× ×	$\times \times$	×			8.94	
	POSITIVE REGULATION OF RESPONSE TO STIMULUS	××××	(XX	×	X	×××	××	$\times \times$	XX		×	×× ×	×	×			8.77	
	REGULATION OF DEVELOPMENTAL PROCESS	$\times$ $\times$	< ×	××	X	×××:	××	$\times \times$	×		×	××××××	×	××			8.68	
	REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT	××	X	×		×××:	×	XX	×		×	XX XXX	×	×			8.39	

1029 1030
1031 1032
1033 1034
1033 1036 1037
1038 1039
1040

1042 1043

medRxiv preprint doi: https://doi.org/10.1101/2023.12.24.23300505; this version posted December 28, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in percetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

1044 Supplementary Figure 4 Performance of individual base-learner classifiers and stack ensemble for a 1045 reduced set of biomarkers, CA19-9, Age, Diabetes, VWF, CPE, CTSV, CEACAM1 and CD160. A Base-learner 1046 performance in the discovery. Each base-learner classifier was developed by training with a recursive feature 1047 elimination technique (RFE) and logistic regression (glm) in samples belonging to each specific diagnosis class 1048 1049 against the same 24 PDACs in the discovery set. The performance reported in A is, nevertheless, of each classifier in the whole discovery set. The performances reported in B correspond to the base-learners developed in the 1050 discovery set but applied to the whole validation set. In C and D the performance of an ensemble GLM stack based 1051 on the base-learners presented in A and B is reported in the discovery and validation sets, respectively. The ROC 1052 AUC significance threshold is represented by a purple dashed line at 0.5. Error bars in figures correspond to 95% 1053 Confidence Intervals (CI), calculated by stratified bootstrapping 2000 times.

1054

1055

medRxiv preprint doi: https://doi.org/10.1101/2023.12.24.23300505; this version posted December 28, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .





1066 1067 1068 Supplementary Figure 5 Feature importance for a reduced 8-marker model following the same principles as those described in Figure 2 A and B. The reduced set of biomarkers was CA19-9, Age, Diabetes, VWF, CPE, CTSV, CEACAM1 and CD160. See also performances in Supplementary Figure 4. Selected features are ranked 1069 from left to right according to the average scaled importance across base learners. See Methods for details. 1070



1072

medRxiv preprint doi: https://doi.org/10.1101/2023.12.24.23300505; this version posted December 28, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

### 1073 1074 1075

1075 **Supplementary Figure 6 Matrix for associated symptoms for each sample**. Each sample in the whole set collected from ADEPTS cohort is represented by the columns. The colour coding corresponds to the diagnosis class associated with each sample. Symptoms are represented in each row. Both columns and rows are clustered according to their symptoms pattern. Black represents presence of sample with the respective symptoms and diagnosis.



1084

 $1080 \\ 1081 \\ 1082 \\ 1083$ 

1085

### 1086 Supplementary Tables

1087

1088 Supplementary Table 1 Quantitative ELISA assays` intra-assay coefficient of variation.

Assay	Dilution factor	CV(%)
CA19-9(A)	1:4	6.9
VWF	1:100	13.5
THBS2	1:10	12.5
PKM/PKM2	1:10	10.3
IL6ST/IL6RB	1:100	-

medRxiv preprint doi: https://doi.org/10.1101/2023.12.24.23300505; this version posted December 28, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in pernetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

## 1095 Supplementary Table 2 Cancer-associated proteins measured on the Olink Oncology II panel used in this

1096 project. The remaining biomarkers were done in-house. The protein names are listed to be consistent with those 1097 provided by Olink.

PODXL	VEGF-A	VEGFR- 2/KDR	VEGFR-3/LFT4	RSP03	IL6	IFN- gamma- R1/IFNGR1
CXCL17	MK/MDK	MIC-A/B	WFDC2	ESM-1	MSLN	CEACAM1
ITGAV	GPC1	SYND1/SDC1	PVRL4/NECTIN4	TXLNA	Gal-1/GAL	LYPD3
IGF1R	LYN	ABL1	EPHA2	CDKN1A	PPY	SCF/KITLG
EGF	AREG/AR	ErbB2/HER2	ErbB3/HER3	ErbB4/HER4	WISP-1/CCN4	WIF-1
TRAIL/TNFSF10	TNFSF13	TNFRSF19	TNFRSF6B	TLR3	SMAD5/MAD5	FADD
KLK8/hK8	KLK11/hK11	KLK13	KLK14/hK14	CPE	XPNPEP2	CTSV
TFPI-2	SCAMP3	GZMB	GZMH	CYR61/CCN1	ADAM8	ADAM-TS 15
FCRLB	TCL1A	CD27	CD48	CD70	CD160	CD207
ANXA1	S100A4	S100A11	VIM	CRNN	DLL1	SEZ6L
FOLR3/FRgamma	5'-NT/NT5E	LY9	CA9/CAIX	FGF-BP1	ICOSLG	FOLR1/FR- alpha
MIA	CEACAM5/CEA	SPARC	HGF	TGFR- 2/TGFRB2	FASLG/FasL	MetAP 2
CXCL13	ITGB5	RET	TGF-alpha/TGFA	TNFRSF4	GPNMB	FUR/FURIN
MUC16						

medRxiv preprint doi: https://doi.org/10.1101/2023.12.24.23300505; this version posted December 28, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

## 1109

Supplementary Table 3 Odds ratios, p values, ROC AUC, sensitivity (Sens), positive predictive value (PPV) and negative predictive value (NPV) for univariate logistic regression models derived in the discovery set. The performances of these model in the validation are presented in Supplementary Table 4. Markers are ranked according to the p values. Spec: specificity.

### 1114

Marker	OR	p value	ROC AUC	Sens at 90% Spec	PPV at 90% Spec	NPV at 90% Spec
CA19 - 9	1.85 (1.54 - 2.26)	1.87E-12	0.79 (0.66 - 0.91)	0.67 (0.5 - 0.83)	0.32 (0.26 - 0.38)	0.97 (0.96 - 0.99)
KITLG	0.23 (0.14 - 0.37)	7.95E-11	0.79 (0.68 - 0.89)	0.5 (0.29 - 0.71)	0.26 (0.17 - 0.34)	0.96 (0.95 - 0.98)
CRP	2.01 (1.59 - 2.61)	4.12E-10	0.84 (0.74 - 0.92)	0.58 (0.38 - 0.83)	0.34 (0.25 - 0.42)	0.96 (0.94 - 0.98)
VWF	3.92 (2.28 - 7.78)	1.89E-09	0.84 (0.76 - 0.9)	0.5 (0.29 - 0.71)	0.26 (0.17 - 0.34)	0.96 (0.95 - 0.98)
SDC1	4.42 (2.56 - 8.01)	8.47E-08	0.79 (0.66 - 0.89)	0.67 (0.46 - 0.83)	0.32 (0.25 - 0.38)	0.97 (0.96 - 0.99)
KDR	0.01 (0.00 - 0.07)	2.02E-07	0.8 (0.72 - 0.87)	0.42 (0.21 - 0.67)	0.23 (0.13 - 0.32)	0.96 (0.94 - 0.97)
TBIL	2.03 (1.55 - 2.75)	2.53E-07	0.72 (0.6 - 0.85)	0.54 (0.29 - 0.71)	0.32 (0.2 - 0.38)	0.96 (0.94 - 0.97)
TNFRSF6B	2.62 (1.80 - 3.94)	3.12E-07	0.75 (0.64 - 0.86)	0.5 (0.29 - 0.71)	0.26 (0.17 - 0.34)	0.96 (0.95 - 0.98)
FASLG	0.20 (0.10 - 0.39)	2.39E-06	0.77 (0.65 - 0.87)	0.46 (0.21 - 0.67)	0.25 (0.13 - 0.32)	0.96 (0.94 - 0.97)
ESM-1	4.84 (2.35 - 10.69)	5.99E-06	0.76 (0.66 - 0.84)	0.29 (0.12 - 0.5)	0.17 (0.08 - 0.27)	0.95 (0.93 - 0.96)
EPHA2	5.15 (2.56 - 10.97)	6.31E-06	0.73 (0.63 - 0.82)	0.29 (0.12 - 0.46)	0.17 (0.08 - 0.25)	0.95 (0.93 - 0.96)
RET	0.18 (0.08 - 0.38)	7.01E-06	0.78 (0.68 - 0.87)	0.42 (0.21 - 0.62)	0.23 (0.13 - 0.31)	0.96 (0.94 - 0.97)
TGFA	0.33 (0.18 - 0.55)	9.61E-06	0.79 (0.69 - 0.87)	0.33 (0.17 - 0.62)	0.19 (0.11 - 0.31)	0.95 (0.94 - 0.97)
MUC16	2.39 (1.63 - 3.65)	1.02E-05	0.72 (0.59 - 0.83)	0.38 (0.21 - 0.58)	0.21 (0.13 - 0.3)	0.95 (0.94 - 0.97)
ITGAV	0.05 (0.01 - 0.19)	1.29E-05	0.78 (0.68 - 0.87)	0.46 (0.17 - 0.67)	0.25 (0.11 - 0.32)	0.96 (0.94 - 0.97)
EGF	0.55 (0.41 - 0.72)	3.77E-05	0.79 (0.71 - 0.87)	0.5 (0.21 - 0.71)	0.26 (0.13 - 0.34)	0.96 (0.94 - 0.98)
ICOSLG	0.04 (0.01 - 0.20)	5.60E-05	0.77 (0.66 - 0.85)	0.29 (0.12 - 0.5)	0.17 (0.08 - 0.26)	0.95 (0.93 - 0.96)
CEACAM5	2.05 (1.46 - 2.94)	6.15E-05	0.72 (0.61 - 0.83)	0.33 (0.17 - 0.58)	0.19 (0.11 - 0.3)	0.95 (0.94 - 0.97)
CTSV	0.27 (0.13 - 0.54)	0.00019	0.73 (0.61 - 0.84)	0.29 (0.08 - 0.5)	0.17 (0.06 - 0.26)	0.95 (0.93 - 0.96)
TFPI2	2.91 (1.65 - 5.38)	0.00024	0.7 (0.58 - 0.8)	0.29 (0.08 - 0.5)	0.17 (0.06 - 0.26)	0.95 (0.93 - 0.96)
WIF1	0.17 (0.06 - 0.45)	0.00031	0.72 (0.61 - 0.82)	0.33 (0.12 - 0.5)	0.19 (0.08 - 0.26)	0.95 (0.93 - 0.96)
TXLNA	2.21 (1.41 - 3.51)	0.00065	0.69 (0.55 - 0.81)	0.42 (0.17 - 0.62)	0.23 (0.11 - 0.31)	0.96 (0.94 - 0.97)
LYPD3	0.24 (0.10 - 0.57)	0.0012	0.68 (0.57 - 0.79)	0.33 (0.17 - 0.58)	0.19 (0.11 - 0.3)	0.95 (0.94 - 0.97)
CA9	2.21 (1.33 - 3.68)	0.0022	0.65 (0.52 - 0.77)	0.29 (0.12 - 0.5)	0.17 (0.08 - 0.26)	0.95 (0.93 - 0.96)
FCRLB	2.24 (1.32 - 3.74)	0.0033	0.66 (0.53 - 0.78)	0.38 (0.17 - 0.58)	0.21 (0.11 - 0.3)	0.95 (0.94 - 0.97)
TCL1A	0.54 (0.35 - 0.82)	0.0033	0.68 (0.57 - 0.78)	0.29 (0.12 - 0.5)	0.17 (0.08 - 0.26)	0.95 (0.93 - 0.96)
MDK	2.42 (1.34 - 4.42)	0.0039	0.66 (0.54 - 0.77)	0.25 (0.08 - 0.46)	0.15 (0.06 - 0.25)	0.94 (0.93 - 0.96)
CDKN1A	1.82 (1.19 - 2.75)	0.0066	0.63 (0.48 - 0.76)	0.33 (0.12 - 0.5)	0.19 (0.08 - 0.26)	0.95 (0.93 - 0.96)
FURIN	0.25 (0.09 - 0.70)	0.0083	0.67 (0.54 - 0.79)	0.29 (0.08 - 0.5)	0.17 (0.06 - 0.26)	0.95 (0.93 - 0.96)
TNFSF13	4.17 (1.43 - 12.15)	0.0093	0.64 (0.54 - 0.75)	0.25 (0.08 - 0.46)	0.15 (0.06 - 0.25)	0.94 (0.93 - 0.96)
GAL	0.16 (0.04 - 0.65)	0.011	0.63 (0.51 - 0.74)	0.25 (0.08 - 0.46)	0.15 (0.06 - 0.25)	0.94 (0.93 - 0.96)
TNFSF10	0.24 (0.08 - 0.72)	0.011	0.67 (0.55 - 0.77)	0.17 (0.04 - 0.38)	0.11 (0.03 - 0.21)	0.94 (0.93 - 0.95)
CPE	0.31 (0.12 - 0.77)	0.012	0.66 (0.54 - 0.77)	0.25 (0.08 - 0.46)	0.15 (0.06 - 0.25)	0.94 (0.93 - 0.96)
WFDC2	3.02 (1.27 - 7.34)	0.012	0.64 (0.53 - 0.75)	0.21 (0.04 - 0.42)	0.13 (0.03 - 0.23)	0.94 (0.93 - 0.96)
PPY	0.74 (0.59 - 0.94)	0.014	0.67 (0.56 - 0.78)	0.21 (0.04 - 0.46)	0.13 (0.03 - 0.25)	0.94 (0.93 - 0.96)

METAP2	1.76 (1.12 - 2.77)	0.015	0.6 (0.44 - 0.74)	0.29 (0.12 - 0.5)	0.17 (0.08 - 0.26)	0.95 (0.93 - 0.96)
XPNPEP2	0.70 (0.50 - 0.93)	0.018	0.6 (0.49 - 0.7)	0.17 (0.04 - 0.33)	0.11 (0.03 - 0.19)	0.94 (0.93 - 0.95)
NECTIN4	2.71 (1.19 - 6.04)	0.018	0.61 (0.5 - 0.72)	0.21 (0.04 - 0.38)	0.13 (0.03 - 0.21)	0.94 (0.93 - 0.95)
Creatinine	0.29 (0.10 - 0.86)	0.024	0.62 (0.49 - 0.73)	0.25 (0.08 - 0.42)	0.18 (0.07 - 0.27)	0.93 (0.92 - 0.95)
KLK8	0.34 (0.13 - 0.88)	0.026	0.61 (0.47 - 0.74)	0.35 (0.08 - 0.54)	0.2 (0.06 - 0.28)	0.95 (0.93 - 0.96)
CD207	0.35 (0.13 - 0.89)	0.028	0.62 (0.51 - 0.72)	0.12 (0 - 0.29)	0.08 (0 - 0.17)	0.93 (0.93 - 0.95)
MIA	0.24 (0.07 - 0.92)	0.038	0.62 (0.49 - 0.73)	0.25 (0.08 - 0.42)	0.15 (0.06 - 0.23)	0.94 (0.93 - 0.96)
GPNMB	9.28 (1.10 - 84.13)	0.040	0.63 (0.52 - 0.74)	0.17 (0.04 - 0.38)	0.11 (0.03 - 0.21)	0.94 (0.93 - 0.95)
ERBB2	3.21 (1.06 - 9.50)	0.040	0.56 (0.41 - 0.71)	0.33 (0.17 - 0.54)	0.19 (0.11 - 0.28)	0.95 (0.94 - 0.96)
DLL1	3.06 (1.05 - 9.11)	0.041	0.58 (0.45 - 0.7)	0.25 (0.08 - 0.46)	0.15 (0.06 - 0.25)	0.94 (0.93 - 0.96)
TNFRSF19	0.45 (0.20 - 0.98)	0.044	0.65 (0.51 - 0.77)	0.33 (0.08 - 0.54)	0.19 (0.06 - 0.28)	0.95 (0.93 - 0.96)
AR	1.47 (1.00 - 2.09)	0.053	0.63 (0.51 - 0.74)	0.21 (0.04 - 0.38)	0.13 (0.03 - 0.21)	0.94 (0.93 - 0.95)
NT5E	1.76 (0.99 - 3.08)	0.053	0.63 (0.51 - 0.74)	0.17 (0.04 - 0.46)	0.11 (0.03 - 0.25)	0.94 (0.93 - 0.96)
THBS2	1.60 (0.98 - 2.69)	0.060	0.62 (0.48 - 0.75)	0.25 (0.08 - 0.46)	0.15 (0.06 - 0.25)	0.94 (0.93 - 0.96)
ADAM8	0.42 (0.16 - 1.04)	0.060	0.6 (0.48 - 0.73)	0.25 (0.08 - 0.46)	0.15 (0.06 - 0.25)	0.94 (0.93 - 0.96)
GZMB	0.57 (0.30 - 1.06)	0.077	0.61 (0.48 - 0.74)	0.25 (0.08 - 0.5)	0.15 (0.06 - 0.26)	0.94 (0.93 - 0.96)
IGF1R	0.37 (0.12 - 1.12)	0.078	0.64 (0.52 - 0.77)	0.29 (0.08 - 0.5)	0.17 (0.06 - 0.26)	0.95 (0.93 - 0.96)
PKM	1.12 (0.98 - 1.30)	0.10	0.57 (0.43 - 0.72)	0.12 (0 - 0.46)	0.1 (0 - 0.29)	0.92 (0.91 - 0.95)
KLK14	0.53 (0.25 - 1.16)	0.11	0.59 (0.48 - 0.7)	0.12 (0 - 0.29)	0.08 (0 - 0.17)	0.93 (0.93 - 0.95)
ERBB3	0.32 (0.08 - 1.32)	0.11	0.59 (0.46 - 0.72)	0.25 (0.08 - 0.42)	0.15 (0.06 - 0.23)	0.94 (0.93 - 0.96)
CRNN	0.67 (0.40 - 1.12)	0.13	0.64 (0.53 - 0.75)	0.21 (0.04 - 0.42)	0.13 (0.03 - 0.23)	0.94 (0.93 - 0.96)
FOLR3	0.85 (0.64 - 1.05)	0.14	0.57 (0.47 - 0.68)	0.12 (0 - 0.29)	0.08 (0 - 0.17)	0.93 (0.93 - 0.95)
CXCL13	0.59 (0.28 - 1.18)	0.14	0.58 (0.43 - 0.71)	0.29 (0.12 - 0.5)	0.17 (0.08 - 0.26)	0.95 (0.93 - 0.962)
SEZ6L	0.39 (0.12 - 1.39)	0.15	0.63 (0.5 - 0.75)	0.29 (0.04 - 0.46)	0.17 (0.03 - 0.25)	0.95 (0.93 - 0.96)
KLK13	0.67 (0.38 - 1.17)	0.16	0.58 (0.45 - 0.72)	0.25 (0.08 - 0.46)	0.15 (0.06 - 0.25)	0.94 (0.93 - 0.96)
S100A11	0.57 (0.23 - 1.24)	0.16	0.54 (0.42 - 0.66)	0.21 (0.08 - 0.38)	0.13 (0.06 - 0.21)	0.94 (0.93 - 0.95)
ITGB5	2.09 (0.72 - 6.18)	0.18	0.46 (0.33 - 0.59)	0.12 (0 - 0.25)	0.08 (0 - 0.15)	0.93 (0.93 - 0.94)
IL6	1.18 (0.91 - 1.46)	0.18	0.61 (0.5 - 0.72)	0.21 (0.04 - 0.38)	0.13 (0.03 - 0.21)	0.94 (0.93 - 0.95)
MICA/B	1.24 (0.91 - 1.88)	0.19	0.62 (0.49 - 0.74)	0.25 (0.08 - 0.46)	0.15 (0.06 - 0.25)	0.94 (0.93 - 0.96)
CXCL17	1.40 (0.84 - 2.30)	0.19	0.55 (0.46 - 0.65)	0.08 (0 - 0.21)	0.06 (0 - 0.13)	0.93 (0.93 - 0.94)
CD70	0.62 (0.30 - 1.27)	0.20	0.58 (0.46 - 0.69)	0.12 (0 - 0.29)	0.08 (0 - 0.17)	0.93 (0.93 - 0.95)
CD160	0.63 (0.30 - 1.28)	0.20	0.57 (0.43 - 0.7)	0.25 (0.08 - 0.46)	0.15 (0.06 - 0.25)	0.94 (0.93 - 0.96)
TLR3	0.70 (0.41 - 1.22)	0.20	0.59 (0.44 - 0.72)	0.17 (0 - 0.38)	0.11 (0 - 0.21)	0.94 (0.93 - 0.95)
VIM	0.81 (0.55 - 1.17)	0.27	0.55 (0.44 - 0.66)	0.12 (0 - 0.29)	0.08 (0 - 0.17)	0.93 (0.93 - 0.95)
IFNGR1	1.99 (0.53 - 6.82)	0.30	0.53 (0.39 - 0.65)	0.12 (0 - 0.29)	0.08 (0 - 0.17)	0.93 (0.93 - 0.95)
FGFBP1	1.70 (0.59 - 4.53)	0.32	0.54 (0.39 - 0.68)	0.21 (0.08 - 0.46)	0.13 (0.06 - 0.25)	0.94 (0.93 - 0.96)
LY9	0.64 (0.24 - 1.70)	0.36	0.56 (0.43 - 0.69)	0.25 (0.08 - 0.46)	0.15 (0.06 - 0.25)	0.94 (0.93 - 0.96)
FOLR1	0.68 (0.28 - 1.65)	0.39	0.59 (0.46 - 0.7)	0.04 (0 - 0.33)	0.03 (0 - 0.19)	0.93 (0.93 - 0.95)
MSLN	1.25 (0.74 - 2.05)	0.40	0.58 (0.49 - 0.66)	0.04 (0 - 0.17)	0.03 (0 - 0.11)	0.93 (0.93 - 0.94)
PODXL	2.39 (0.31 - 18.29)	0.40	0.53 (0.4 - 0.67)	0.21 (0.04 - 0.42)	0.13 (0.03 - 0.23)	0.94 (0.93 - 0.96)
GZMH	1.23 (0.74 - 1.95)	0.41	0.47 (0.34 - 0.6)	0.04 (0 - 0.17)	0.03 (0 - 0.11)	0.93 (0.93 - 0.94)
S100A4	0.81 (0.46 - 1.34)	0.42	0.57 (0.42 - 0.7)	0.33 (0.17 - 0.5)	0.19 (0.11 - 0.27)	0.95 (0.94 - 0.96)
ERBB4	0.64 (0.20 - 2.08)	0.45	0.57 (0.43 - 0.69)	0.12 (0 - 0.38)	0.08 (0 - 0.21)	0.93 (0.93 - 0.95)

TGFBR2	0.71 (0.28 - 1.75)	0.46	0.59 (0.45 - 0.71)	0.12 (0 - 0.29)	0.08 (0 - 0.17)	0.93 (0.93 - 0.95)
SMAD5	0.57 (0.15 - 2.95)	0.46	0.61 (0.52 - 0.71)	0.04 (0 - 0.12)	0.03 (0 - 0.08)	0.93 (0.93 - 0.94)
VEGFA	0.78 (0.38 - 1.57)	0.49	0.52 (0.39 - 0.65)	0.17 (0.04 - 0.33)	0.11 (0.03 - 0.19)	0.94 (0.93 - 0.95)
CD48	0.66 (0.19 - 2.29)	0.50	0.53 (0.4 - 0.66)	0.21 (0.04 - 0.38)	0.13 (0.03 - 0.21)	0.94 (0.93 - 0.95)
RSP03	1.16 (0.67 - 1.86)	0.57	0.49 (0.38 - 0.59)	0 (0 - 0)	0 (0 - 0)	0.93 (0.93 - 0.93)
CCN4	0.82 (0.38 - 1.64)	0.59	0.55 (0.42 - 0.68)	0.17 (0.04 - 0.33)	0.11 (0.03 - 0.19)	0.94 (0.93 - 0.95)
IL6ST	0.87 (0.60 - 2.13)	0.59	0.66 (0.52 - 0.8)	0.38 (0.21 - 0.58)	0.21 (0.13 - 0.3)	0.95 (0.94 - 0.97)
LYN	1.22 (0.39 - 2.70)	0.69	0.53 (0.38 - 0.67)	0.25 (0.08 - 0.42)	0.15 (0.06 - 0.23)	0.94 (0.93 - 0.96)
SCAMP3	0.94 (0.68 - 1.26)	0.70	0.5 (0.38 - 0.62)	0 (0 - 0)	0 (0 - 0)	0.93 (0.93 - 0.93)
CCN1	1.11 (0.62 - 2.02)	0.72	0.52 (0.4 - 0.63)	0 (0 - 0)	0 (0 - 0)	0.93 (0.93 - 0.93)
SPARC	0.61 (0.05 - 9.54)	0.72	0.48 (0.37 - 0.59)	0 (0 - 0)	0 (0 - 0)	0.93 (0.93 - 0.93)
TNFRSF4	1.13 (0.55 - 2.19)	0.73	0.5 (0.37 - 0.64)	0.17 (0.04 - 0.38)	0.11 (0.03 - 0.21)	0.94 (0.93 - 0.95)
ABL1	0.92 (0.55 - 1.46)	0.75	0.48 (0.34 - 0.6)	0.08 (0 - 0.21)	0.06 (0 - 0.13)	0.93 (0.93 - 0.94)
CEACAM1	0.83 (0.34 - 4.06)	0.75	0.54 (0.42 - 0.65)	0.17 (0 - 0.29)	0.11 (0 - 0.17)	0.94 (0.93 - 0.95)
FADD	1.07 (0.65 - 1.64)	0.79	0.55 (0.42 - 0.66)	0.08 (0 - 0.25)	0.06 (0 - 0.15)	0.93 (0.93 - 0.94)
ADAMTS15	1.09 (0.58 - 2.06)	0.79	0.51 (0.39 - 0.64)	0.12 (0 - 0.25)	0.08 (0 - 0.15)	0.93 (0.93 - 0.943)
CD27	1.09 (0.45 - 2.58)	0.84	0.52 (0.39 - 0.65)	0.12 (0 - 0.29)	0.08 (0 - 0.17)	0.93 (0.93 - 0.95)
HGF	1.05 (0.47 - 2.22)	0.91	0.55 (0.41 - 0.7)	0.25 (0.08 - 0.42)	0.15 (0.06 - 0.23)	0.94 (0.93 - 0.96)
KLK11	0.96 (0.40 - 2.23)	0.92	0.49 (0.39 - 0.61)	0.08 (0 - 0.25)	0.06 (0 - 0.15)	0.93 (0.93 - 0.94)
ANXA1	0.98 (0.63 - 1.51)	0.94	0.51 (0.39 - 0.63)	0.04 (0 - 0.17)	0.03 (0 - 0.11)	0.93 (0.93 - 0.94)
FLT4	0.95 (0.18 - 5.70)	0.96	0.52 (0.4 - 0.65)	0.08 (0 - 0.21)	0.06 (0 - 0.13)	0.93 (0.93 - 0.94)
GPC1	1.00 (0.37 - 2.75)	1.00	0.54 (0.41 - 0.67)	0.17 (0.04 - 0.33)	0.11 (0.03 - 0.19)	0.94 (0.93 - 0.95)

Supplementary Table 4 ROC AUC, sensitivity (Sens), positive predictive value (PPV) and negative predictive value (NPV) in the validation set of the univariate logistic regression model derived in the discovery set. Markers are ranked according to their respective p values in the discovery set (see Supplementary Table 3). Spec: specificity.

Marker	ROC AUC	Sens at 90% Spec	PPV at 90% Spec	NPV at 90% Spec
CA19 - 9	0.80 (0.66 - 0.93)	0.65 (0.48 - 0.87)	0.49 (0.41 - 0.56)	0.95 (0.92 - 0.98)
KITLG	0.82 (0.72 - 0.90)	0.48 (0.22 - 0.70)	0.41 (0.24 - 0.50)	0.92 (0.89 - 0.95)
CRP	0.85 (0.76 - 0.92)	0.59 (0.32 - 0.86)	0.47 (0.32 - 0.56)	0.94 (0.90 - 0.98)
VWF	0.74 (0.64 - 0.84)	0.26 (0.04 - 0.52)	0.27 (0.06 - 0.43)	0.89 (0.87 - 0.93)
SDC1	0.72 (0.59 - 0.83)	0.30 (0.09 - 0.61)	0.31 (0.11 - 0.47)	0.90 (0.87 - 0.94)
KDR	0.77 (0.67 - 0.86)	0.39 (0.17 - 0.61)	0.36 (0.20 - 0.47)	0.91 (0.88 - 0.94)
TBIL	0.67 (0.55 - 0.77)	0.23 (0.09 - 0.41)	0.25 (0.12 - 0.38)	0.89 (0.87 - 0.91)
TNFRSF6B	0.72 (0.60 - 0.83)	0.39 (0.13 - 0.61)	0.36 (0.16 - 0.47)	0.91 (0.88 - 0.94)
FASLG	0.74 (0.64 - 0.84)	0.26 (0.09 - 0.52)	0.27 (0.11 - 0.43)	0.89 (0.87 - 0.93)
ESM1	0.73 (0.62 - 0.82)	0.30 (0.13 - 0.52)	0.31 (0.16 - 0.43)	0.90 (0.88 - 0.93)
EPHA2	0.70 (0.56 - 0.82)	0.39 (0.17 - 0.61)	0.36 (0.20 - 0.47)	0.91 (0.88 - 0.94)
RET	0.69 (0.59 - 0.78)	0.26 (0.09 - 0.43)	0.27 (0.11 - 0.39)	0.89 (0.87 - 0.92)
TGFA	0.71 (0.59 - 0.81)	0.26 (0.09 - 0.48)	0.27 (0.11 - 0.41)	0.89 (0.87 - 0.92)
MUC16	0.71 (0.58 - 0.84)	0.48 (0.22 - 0.70)	0.41 (0.24 - 0.50)	0.92 (0.89 - 0.95)
ITGAV	0.77 (0.67 - 0.85)	0.39 (0.13 - 0.57)	0.36 (0.16 - 0.45)	0.91 (0.88 - 0.94)
EGF	0.74 (0.61 - 0.85)	0.52 (0.13 - 0.70)	0.43 (0.16 - 0.50)	0.93 (0.88 - 0.95)

ICOSLG	0.69 (0.59 - 0.79)	0.30 (0.09 - 0.48)	0.31 (0.11 - 0.41)	0.90 (0.87 - 0.92)
CEACAM5	0.72 (0.60 - 0.83)	0.35 (0.13 - 0.52)	0.33 (0.16 - 0.43)	0.91 (0.88 - 0.93)
CTSV	0.74 (0.63 - 0.84)	0.26 (0.09 - 0.57)	0.27 (0.11 - 0.45)	0.89 (0.87 - 0.94)
TFPI2	0.67 (0.54 - 0.78)	0.22 (0.04 - 0.48)	0.24 (0.06 - 0.41)	0.89 (0.87 - 0.92)
WIF1	0.63 (0.51 - 0.74)	0.17 (0.00 - 0.39)	0.20 (0.00 - 0.36)	0.88 (0.86 - 0.91)
TXLNA	0.64 (0.51 - 0.75)	0.22 (0.09 - 0.43)	0.24 (0.11 - 0.39)	0.89 (0.87 - 0.92)
LYPD3	0.67 (0.54 - 0.79)	0.22 (0.04 - 0.43)	0.24 (0.06 - 0.39)	0.89 (0.87 - 0.92)
CA9	0.73 (0.64 - 0.82)	0.17 (0.04 - 0.35)	0.20 (0.06 - 0.33)	0.88 (0.87 - 0.91)
FCRLB	0.69 (0.59 - 0.79)	0.26 (0.04 - 0.43)	0.27 (0.06 - 0.39)	0.89 (0.87 - 0.92)
TCL1A	0.58 (0.45 - 0.70)	0.17 (0.04 - 0.39)	0.20 (0.06 - 0.36)	0.88 (0.87 - 0.91)
MDK	0.70 (0.59 - 0.81)	0.35 (0.17 - 0.57)	0.33 (0.20 - 0.45)	0.91 (0.88 - 0.94)
CDKN1A	0.62 (0.49 - 0.74)	0.13 (0.00 - 0.43)	0.16 (0.00 - 0.39)	0.88 (0.86 - 0.92)
FURIN	0.64 (0.51 - 0.77)	0.22 (0.04 - 0.48)	0.24 (0.06 - 0.41)	0.89 (0.87 - 0.92)
TNFSF13	0.64 (0.52 - 0.76)	0.22 (0.04 - 0.43)	0.24 (0.06 - 0.39)	0.89 (0.87 - 0.92)
GAL	0.61 (0.47 - 0.72)	0.17 (0.04 - 0.39)	0.20 (0.06 - 0.36)	0.88 (0.87 - 0.91)
TNFSF10	0.66 (0.54 - 0.77)	0.22 (0.04 - 0.39)	0.24 (0.06 - 0.36)	0.89 (0.87 - 0.91)
CPE	0.64 (0.50 - 0.76)	0.22 (0.04 - 0.43)	0.24 (0.06 - 0.39)	0.89 (0.87 - 0.92)
WFDC2	0.75 (0.62 - 0.86)	0.30 (0.09 - 0.61)	0.31 (0.11 - 0.47)	0.90 (0.87 - 0.94)
PPY	0.62 (0.51 - 0.73)	0.17 (0.04 - 0.35)	0.20 (0.06 - 0.33)	0.88 (0.87 - 0.91)
METAP2	0.62 (0.47 - 0.75)	0.26 (0.09 - 0.48)	0.27 (0.11 - 0.41)	0.89 (0.87 - 0.92)
XPNPEP2	0.57 (0.45 - 0.69)	0.09 (0.00 - 0.30)	0.11 (0.00 - 0.31)	0.87 (0.86 - 0.90)
NECTIN4	0.62 (0.49 - 0.75)	0.26 (0.04 - 0.48)	0.27 (0.06 - 0.41)	0.89 (0.87 - 0.92)
Creatinine	0.44 (0.29 - 0.58)	0.09 (0.00 - 0.27)	0.12 (0.00 - 0.29)	0.87 (0.86 - 0.89)
KLK8	0.65 (0.52 - 0.78)	0.26 (0.04 - 0.48)	0.27 (0.06 - 0.41)	0.89 (0.87 - 0.92)
CD207	0.51 (0.38 - 0.64)	0.04 (0.00 - 0.17)	0.06 (0.00 - 0.20)	0.87 (0.86 - 0.88)
MIA	0.51 (0.40 - 0.63)	0.04 (0.00 - 0.17)	0.06 (0.00 - 0.20)	0.87 (0.86 - 0.88)
GPNMB	0.70 (0.58 - 0.81)	0.30 (0.09 - 0.52)	0.31 (0.11 - 0.43)	0.90 (0.87 - 0.93)
ERBB2	0.47 (0.34 - 0.61)	0.13 (0.00 - 0.30)	0.16 (0.00 - 0.31)	0.88 (0.86 - 0.90)
DLL1	0.65 (0.52 - 0.78)	0.26 (0.04 - 0.52)	0.27 (0.06 - 0.43)	0.89 (0.87 - 0.93)
TNFRSF19	0.52 (0.39 - 0.65)	0.13 (0.00 - 0.30)	0.16 (0.00 - 0.31)	0.88 (0.86 - 0.90)
AR	0.70 (0.57 - 0.81)	0.22 (0.04 - 0.52)	0.24 (0.06 - 0.43)	0.89 (0.87 - 0.93)
NT5E	0.68 (0.55 - 0.80)	0.22 (0.04 - 0.48)	0.24 (0.06 - 0.41)	0.89 (0.87 - 0.92)
THBS2	0.73 (0.61 - 0.84)	0.43 (0.22 - 0.65)	0.39 (0.24 - 0.49)	0.92 (0.89 - 0.95)
ADAM8	0.50 (0.38 - 0.62)	0.09 (0.00 - 0.26)	0.11 (0.00 - 0.27)	0.87 (0.86 - 0.89)
GZMB	0.60 (0.47 - 0.73)	0.22 (0.09 - 0.39)	0.24 (0.11 - 0.36)	0.89 (0.87 - 0.91)
IGF1R	0.51 (0.38 - 0.64)	0.09 (0.00 - 0.22)	0.11 (0.00 - 0.24)	0.87 (0.86 - 0.89)
РКМ	0.61 (0.46 - 0.75)	0.23 (0.05 - 0.45)	0.25 (0.06 - 0.40)	0.89 (0.86 - 0.92)
KLK14	0.51 (0.37 - 0.65)	0.22 (0.04 - 0.39)	0.24 (0.06 - 0.36)	0.89 (0.87 - 0.91)
ERBB3	0.61 (0.50 - 0.72)	0.13 (0.00 - 0.35)	0.16 (0.00 - 0.33)	0.88 (0.86 - 0.91)
CRNN	0.68 (0.57 - 0.78)	0.17 (0.04 - 0.35)	0.20 (0.06 - 0.33)	0.88 (0.87 - 0.91)
FOLR3	0.54 (0.44 - 0.65)	0.09 (0.00 - 0.22)	0.11 (0.00 - 0.24)	0.87 (0.86 - 0.89)
CXCL13	0.44 (0.31 - 0.58)	0.00 (0.00 - 0.13)	0.00 (0.00 - 0.16)	0.86 (0.86 - 0.88)
SEZ6L	0.61 (0.48 - 0.73)	0.17 (0.04 - 0.35)	0.20 (0.06 - 0.33)	0.88 (0.87 - 0.91)

KLK13	0.63 (0.51 - 0.74)	0.09 (0.00 - 0.26)	0.11 (0.00 - 0.27)	0.87 (0.86 - 0.89)
S100A11	0.58 (0.45 - 0.70)	0.17 (0.00 - 0.35)	0.20 (0.00 - 0.33)	0.88 (0.86 - 0.91)
ITGB5	0.50 (0.36 - 0.62)	0.00 (0.00 - 0.13)	0.00 (0.00 - 0.16)	0.86 (0.86 - 0.88)
IL6	0.69 (0.58 - 0.80)	0.13 (0.00 - 0.39)	0.16 (0.00 - 0.36)	0.88 (0.86 - 0.91)
MICA/B	0.58 (0.45 - 0.69)	0.13 (0.00 - 0.30)	0.16 (0.00 - 0.31)	0.88 (0.86 - 0.90)
CXCL17	0.52 (0.41 - 0.64)	0.04 (0.00 - 0.17)	0.06 (0.00 - 0.20)	0.87 (0.86 - 0.88)
CD70	0.49 (0.35 - 0.61)	0.09 (0.00 - 0.26)	0.11 (0.00 - 0.27)	0.87 (0.86 - 0.89)
CD160	0.51 (0.36 - 0.65)	0.09 (0.00 - 0.26)	0.11 (0.00 - 0.27)	0.87 (0.86 - 0.89)
TLR3	0.68 (0.54 - 0.80)	0.43 (0.17 - 0.65)	0.39 (0.20 - 0.49)	0.92 (0.88 - 0.95)
VIM	0.49 (0.36 - 0.62)	0.13 (0.00 - 0.26)	0.16 (0.00 - 0.27)	0.88 (0.86 - 0.89)
IFNGR1	0.54 (0.40 - 0.69)	0.13 (0.00 - 0.35)	0.16 (0.00 - 0.33)	0.88 (0.86 - 0.91)
FGFBP1	0.62 (0.49 - 0.75)	0.22 (0.09 - 0.43)	0.24 (0.11 - 0.39)	0.89 (0.87 - 0.92)
LY9	0.49 (0.36 - 0.62)	0.04 (0.00 - 0.17)	0.06 (0.00 - 0.20)	0.87 (0.86 - 0.88)
FOLR1	0.51 (0.37 - 0.63)	0.09 (0.00 - 0.22)	0.11 (0.00 - 0.24)	0.87 (0.86 - 0.89)
MSLN	0.67 (0.56 - 0.79)	0.35 (0.00 - 0.52)	0.33 (0.00 - 0.43)	0.91 (0.86 - 0.93)
PODXL	0.47 (0.34 - 0.61)	0.09 (0.00 - 0.26)	0.11 (0.00 - 0.27)	0.87 (0.86 - 0.89)
GZMH	0.47 (0.33 - 0.60)	0.13 (0.00 - 0.30)	0.16 (0.00 - 0.31)	0.88 (0.86 - 0.90)
S100A4	0.54 (0.41 - 0.66)	0.13 (0.00 - 0.26)	0.16 (0.00 - 0.27)	0.88 (0.86 - 0.89)
ERBB4	0.48 (0.34 - 0.60)	0.09 (0.00 - 0.22)	0.11 (0.00 - 0.24)	0.87 (0.86 - 0.89)
TGFBR2	0.49 (0.36 - 0.63)	0.00 (0.00 - 0.17)	0.00 (0.00 - 0.20)	0.86 (0.86 - 0.88)
SMAD5	0.62 (0.51 - 0.73)	0.04 (0.00 - 0.22)	0.06 (0.00 - 0.24)	0.87 (0.86 - 0.89)
VEGFA	0.53 (0.40 - 0.65)	0.09 (0.00 - 0.26)	0.11 (0.00 - 0.27)	0.87 (0.86 - 0.89)
CD48	0.51 (0.39 - 0.64)	0.04 (0.00 - 0.22)	0.06 (0.00 - 0.24)	0.87 (0.86 - 0.89)
RSPO3	0.48 (0.35 - 0.61)	0.09 (0.00 - 0.26)	0.11 (0.00 - 0.27)	0.87 (0.86 - 0.89)
CCN4	0.62 (0.49 - 0.74)	0.22 (0.04 - 0.43)	0.24 (0.06 - 0.39)	0.89 (0.87 - 0.92)
IL6ST	0.68 (0.52 - 0.81)	0.39 (0.22 - 0.61)	0.36 (0.24 - 0.47)	0.91 (0.89 - 0.94)
LYN	0.52 (0.39 - 0.65)	0.22 (0.04 - 0.39)	0.24 (0.06 - 0.36)	0.89 (0.87 - 0.91)
SCAMP3	0.49 (0.38 - 0.61)	0.00 (0.00 - 0.17)	0.00 (0.00 - 0.20)	0.86 (0.86 - 0.88)
CCN1	0.50 (0.40 - 0.60)	0.00 (0.00 - 0.04)	0.00 (0.00 - 0.06)	0.86 (0.86 - 0.87)
SPARC	0.52 (0.40 - 0.64)	0.04 (0.00 - 0.26)	0.06 (0.00 - 0.27)	0.87 (0.86 - 0.89)
TNFRSF4	0.64 (0.51 - 0.76)	0.26 (0.00 - 0.48)	0.27 (0.00 - 0.41)	0.89 (0.86 - 0.92)
ABL1	0.51 (0.39 - 0.63)	0.00 (0.00 - 0.13)	0.00 (0.00 - 0.16)	0.86 (0.86 - 0.88)
CEACAM1	0.54 (0.41 - 0.66)	0.17 (0.04 - 0.35)	0.20 (0.06 - 0.33)	0.88 (0.87 - 0.91)
FADD	0.55 (0.44 - 0.66)	0.00 (0.00 - 0.13)	0.00 (0.00 - 0.16)	0.86 (0.86 - 0.88)
ADAMTS15	0.52 (0.39 - 0.65)	0.13 (0.00 - 0.26)	0.16 (0.00 - 0.27)	0.88 (0.86 - 0.89)
CD27	0.61 (0.47 - 0.74)	0.26 (0.09 - 0.52)	0.27 (0.11 - 0.43)	0.89 (0.87 - 0.93)
HGF	0.51 (0.38 - 0.64)	0.13 (0.00 - 0.30)	0.16 (0.00 - 0.31)	0.88 (0.86 - 0.90)
KLK11	0.59 (0.46 - 0.70)	0.13 (0.00 - 0.30)	0.16 (0.00 - 0.31)	0.88 (0.86 - 0.90)
ANXA1	0.50 (0.37 - 0.62)	0.09 (0.00 - 0.22)	0.11 (0.00 - 0.24)	0.87 (0.86 - 0.89)
FLT4	0.50 (0.36 - 0.62)	0.13 (0.00 - 0.26)	0.16 (0.00 - 0.27)	0.88 (0.86 - 0.89)
GPC1	0.57 (0.42 - 0.71)	0.26 (0.09 - 0.48)	0.27 (0.11 - 0.41)	0.89 (0.87 - 0.92)

medRxiv preprint doi: https://doi.org/10.1101/2023.12.24.23300505; this version posted December 28, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in pernetuity

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

## 1139 Supplementary Table 5 Stack logistic regression model coefficient estimates and respective

- **95% confidence interval (CI) limits and p values.** See statistical analysis sub-section in Methods for
- 1141 the detailed description of the stacking procedure. This model was developed in the discovery set.

	Coefficient Estimate	CI 2.5%	CI 97.5%	p value
Intercept	-1.47	-2.34	-0.73	0.00033
Diagnosis				
Healthy	2.50	1.75	3.45	5.41×10 <sup>-9</sup>
Chronic Pancreatitis	2.30	1.57	3.20	2.26×10 <sup>-8</sup>
IgG4 Disease	2.08	1.26	3.07	4.98×10 <sup>-6</sup>
Irritable Bowel Syndrome	1.92	1.08	2.86	1.61×10 <sup>-5</sup>
Other Biliary Duct Disease	2.29	1.15	3.56	0.00016
Sphincter of Oddi Dysfunction	1.64	0.73	2.65	0.00063
No Relevant Diagnosis	-1.73	-3.23	-0.39	0.015
Other Cancer	0.77	0.076	1.51	0.032
Pancreatic Cyst	-1.52	-3.02	-0.17	0.035
Gastritis/Reflux Disease	0.53	-0.44	1.53	0.28
Familial Pancreatic Cancer	0.49	-0.41	1.41	0.29
Acute Pancreatitis	0.34	-0.29	1.027	0.31
Liver Disease	0.38	-0.35	1.14	0.31
Isolated LFTs Derangement	-0.63	-2.03	0.60	0.34
Non-Specific Abdominal Pain	0.301	-0.47	1.05	0.43
Gallstone Disease	0.18	-0.67	1.07	0.68

medRxiv preprint doi: https://doi.org/10.1101/2023.12.24.23300505; this version posted December 28, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

1151 1152 1153 Supplementary Table 6 Discovery set data and univariate association with PDAC status. Odds ratios (OR),

95% confidence intervals (CI) and p values were calculated according to a logistic regression model with a bias

reduction method (see statistical section in Methods).

## 1154

Variable		Cases	5	Co	ontrols	OR		p va	lue
Number of samples		24		333		-		-	
Mean age at sample dra	w (yr) (range)	70.79 (43.00	-91.00)	58.39(1	9.00-89.00)	1.07 (1.03	- 1.11)	4.686	e-05
Mean BMI (kg/m2) (rang	je)	25.46 (19.81	-41.35)	25.41 (1	15.22-42.19)	1.01 (0.89	-1.12)	0.8	37
Gender									
	Male	18			121	4.98 (2.08 -	- 13.50)	0.00	023
	Female	6			212				
Diabetes									
	yes	5			52				
	no	281			19	1.51 (0.51	- 3.84)	0.4	13
Ethnicity									
	Caucasian	11			189				
	Unknown	9			99				
Asian		3		15		1.17 (0.70	– 2.02)	0.5	56
Other		1		13					
	Afro/Caribbean	0			17				

#### Supplementary Table 7 Validation set data and univariate association with PDAC status. Odds ratios (OR), 95% confidence intervals (CI) and p values were calculated according to a logistic regression 1165 model with a bias reduction method (see statistical section in Methods).

Variable		Cases	Controls	OR	p value
Number of Samples		23	159	-	-
Mean age at sample draw	r (yr) (range)	68.61 (53.00 - 83.0	0) 57.94 (21.00 - 93.00)	1.06 (1.02 -1.04)	0.00071
Mean BMI (kg/m2) (range	)	24.18 (12.04 - 31.6	2) 25.64 (17.60 - 38.30)	0.90 (0.78-1.01)	0.080
Gender					
	Male	14	58	2.65 (1.11 – 6.58)	0.028
	Female	9	101		
Diabetes					
	yes	5	52		
	no	281	19	1.57 (0.51 – 4.23)	0.41
Ethnicity					
	Caucasian	10	102		
	Unknown	12	32		
	Asian	3	15	2.66 (1.42 – 5.17)	0.0020
	Other	1	5		
At	fro/Caribbean	0	5		

# **Supplementary Table 8 Type and number of subjects with other cancers in the ADEPTS cohort.** See also Figure 1. 1175

Other Cancer	Number of subjects
Possible gallbladder cancer	1
Low grade dysplasia on ampulla of Vater (Incidental finding)	1
Hilar cholangiocarcinoma, treated Nov 2017	1
Low anal moderately differentiated adenocarcinoma	1
Cholangiocarcinoma, primary sclerosing cholangitis	1
PNET (insulinoma)	1
Bowel cancer in 2011	1
Prostate cancer	1

Supplementary Table 9 Values corresponding to Figure 4. Only ADEPTS samples were considered for this association study. Given that symptoms were not considered in the training of the classifiers, we concatenate ADEPTS samples in the discovery and validation sets to verify the associations of symptoms and PDAC. A univariate logistic regression model with bias correction was used for each symptom to test the association with PDAC.

	Number of subjects					
	Yes		No			
Symptoms	Control	Case	Control Case		OR (95% CI)	p value
Jaundice	18	22	401	23	20.78 (9.98 - 44.35)	3.22×10 <sup>-15</sup>
Weight Loss	39	17	380	28	5.91 (2.96 - 11.62)	1.44×10 <sup>-06</sup>
Asymptomatic	96	3	323	42	0.28 (0.07- 0.74)	0.0077
Reflux	38	0	381	45	0.11 (0.00 - 0.79)	0.022
Bloating	31	0	388	45	0.14 (0.00 - 0.99)	0.048
Dyspepsia	30	0	389	45	0.14 (0.00 - 1.03)	0.054
Abdominal Pain	198	16	221	29	0.62 (0.33 - 1.16)	0.14
Nausea	20	0	399	45	0.21 (0.00 - 1.60)	0.17
Vomiting	19	4	400	41	2.23 (0.67 - 6.03)	0.17
Asymptomatic LFT Derangement	52	8	367	37	1.59 (0.67 - 3.39)	0.28
Anaemia	24	1	395	44	0.54 (0.06 - 2.18)	0.44
Back Pain	1	0	418	45	3.07 (0.02 - 58.34)	0.54
Heartburn	9	0	410	45	0.47 (0.00 - 3.85)	0.57
Change In Bowel Habit	58	7	361	38	1.20 (0.49 - 2.62)	0.67
Rectal Bleeding	10	1	409	44	1.31 (0.14 - 5.80)	0.76
Dysphagia	16	1	403	44	0.82 (0.09 - 3.42)	0.82

1208 1209 1210 1211 1212 Supplementary Table 10 Performance model rank summary for selected models in symptomatic patients. The probability values used to calculate the performance metrics were generated with each model developed in the training set and reported in the main text. Probability values for symptomatic patients belonging to the training set and validation set were concatenated to generate the ROC curves. Only ADEPTS samples had symptoms information. A. L. Derang.: Asymptomatic LFT Derangement. B. Pain: Back Pain. C. B. Habit: Change in Bowel 1213 Habit. W. Loss: Weight Loss. Here, only the ranks of the performances are provided. For the respective performance values see Table 2 in the main text.

Models	Metric	A.L.Derang.	A.Pain	A.B. Habit	W. Loss	Jaundice	Geometric mean rank	Mean across all metrics
	ROC	3	3	3	3	3	3.00	
CA 10.0	Sens90	3	3	2	3	3	2.77	0.00
CA 19-9	PPV90	3	3	2	3	3	2.77	2.03
	NPV90	3	3	2	3	3	2.77	
	ROC	1	1	1	1	1	1.00	
Index	Sens90	2	1	1	1	2	1.32	1 16
signature	PPV90	2	1	1	1	1	1.15	1.10
	NPV90	1	1	1	1	2	1.15	
	ROC	2	2	2	2	2	2.00	
Reduced	Sens90	1	2	3	2	1	1.64	4 70
signature	PPV90	1	2	3	2	2	1.89	1.79
	NPV90	1	2	3	2	1	1.64	

medRxiv preprint doi: https://doi.org/10.1101/2023.12.24.23300505; this version posted December 28, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Supplementary Table 11 Pairwise area under receiver operating characteristic curve comparison p-values for the selected models in Table 2 (main text). Only ADEPTS samples had symptoms information. A. L. Derang.: Asymptomatic LFT Derangement. B. Pain: Back Pain. C. B. Habit: Change in Bowel Habit. W. Loss: Weight Loss. For the respective performance values see Table 2 in the main text. Models in rows for each symptom are compared with those in the columns for the same symptom. 10000 bootstraps were constructed to test the significance of the difference in performance being lower.

1229

Symptom (Yes)		Reduced signature	Index signature
A.L.Derang.	CA19-9	3.89×10 <sup>-07</sup>	7.70×10 <sup>-26</sup>
	Reduced signature	-	0.25
A. Pain	CA19-9	2.19×10 <sup>-15</sup>	2.83×10 <sup>-93</sup>
	Reduced signature	-	1.08×10 <sup>-06</sup>
A. B. Habit	CA19-9	0.0018	1.48×10 <sup>-28</sup>
	Reduced signature	-	0.020
W.Loss	CA19-9	2.04×10 <sup>-09</sup>	1.38×10 <sup>-14</sup>
	Reduced signature		0.018
Jaundice	CA19-9	0.013	3.34×10 <sup>-07</sup>
	Reduced signature	-	0.069

- 1230
- 1231
- 1232
- 1233
- 1234
- 1235
- 1236

## 1237 **References**

1238

Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. The Lancet. 2016;388:73 85.

1241 2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global

1242 Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36
1243 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians. 2021;71:209-49.

Carioli G, Malvezzi M, Bertuccio P, Boffetta P, Levi F, Vecchia CL, et al. European
 cancer mortality predictions for the year 2021 with focus on pancreatic and female lung
 cancer. Annals of Oncology. 2021;32:478-87.

Dalmartello M, La Vecchia C, Bertuccio P, Boffetta P, Levi F, Negri E, et al. European
 cancer mortality predictions for the year 2022 with focus on ovarian cancer. Ann Oncol.
 2022;33(3):330-9.

1250 5. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM.

Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver,and Pancreas Cancers in the United States. Cancer Research. 2014;74:2913-21.

1253 6. Huang J, Lok V, Ngai CH, Zhang L, Yuan J, Lao XQ, et al. Worldwide Burden of, Risk

1254 Factors for, and Trends in Pancreatic Cancer. Gastroenterology. 2021;160:744-54.

medRxiv preprint doi: https://doi.org/10.1101/2023.12.24.23300505; this version posted December 28, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

1255 7. Marchegiani G, Andrianello S, Malleo G, De Gregorio L, Scarpa A, Mino-Kenudson M, 1256 et al. Does Size Matter in Pancreatic Cancer?: Reappraisal of Tumour Dimension as a 1257 Predictor of Outcome Beyond the TNM. Annals of Surgery. 2017;266(1). 1258 Zerboni G, Signoretti M, Crippa S, Falconi M, Arcidiacono PG, Capurso G. Systematic 8. 1259 review and meta-analysis: Prevalence of incidentally detected pancreatic cystic lesions in 1260 asymptomatic individuals. Pancreatology. 2019;19:2-9. 1261 Pereira SP, Oldfield L, Ney A, Hart PA, Keane MG, Pandol SJ, et al. Early detection of 9. 1262 pancreatic cancer. The Lancet Gastroenterology and Hepatology. 2020. 1263 10. Aslanian HR, Lee JH, Canto MI. AGA Clinical Practice Update on Pancreas Cancer 1264 Screening in High-Risk Individuals: Expert Review. Gastroenterology. 2020;159:358-62. 1265 11. Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, et al. Screening 1266 for Pancreatic Cancer. JAMA. 2019;322:438-. 1267 Chhoda A, Vodusek Z, Wattamwar K, Mukherjee E, Gunderson C, Grimshaw A, et al. 12. 1268 Late-Stage Pancreatic Cancer Detected During High-Risk Individual Surveillance: A 1269 Systematic Review and Meta-Analysis. Gastroenterology. 2022;162:786-98. 1270 13. European evidence-based guidelines on pancreatic cystic neoplasms. Gut. 1271 2018;67:789-804. 1272 Walter FM, Mills K, Mendonça SC, Abel GA, Basu B, Carroll N, et al. Symptoms and 14. 1273 patient factors associated with diagnostic intervals for pancreatic cancer (SYMPTOM 1274 pancreatic study): a prospective cohort study. The Lancet Gastroenterology & Hepatology. 1275 2016;1:298-306. 1276 15. Lukacs G, Kovacs A, Csanadi M, Moizs M, Repa I, Kalo Z, et al. Benefits Of Timely Care 1277 In Pancreatic Cancer: A Systematic Review To Navigate Through The Contradictory Evidence. 1278 Cancer Manag Res. 2019;11:9849-61. 1279 16. Yu J, Blackford AL, Dal Molin M, Wolfgang CL, Goggins M. Time to progression of 1280 pancreatic ductal adenocarcinoma from low-to-high tumour stages. Gut. 2015;64(11):1783-1281 9. 1282 17. Ahn SJ, Choi SJ, Kim HS. Time to Progression of Pancreatic Cancer: Evaluation with 1283 Multi-Detector Computed Tomography. J Gastrointest Cancer. 2017;48(2):164-9. 1284 Lyratzopoulos G, Wardle J, Rubin G. Rethinking diagnostic delay in cancer: how 18. 1285 difficult is the diagnosis? BMJ. 2014;349:g7400. 1286 Escorza-Calzada S, Rosas-Camargo V, Melchor-Ruan J, Meneses-Medina M, Cedro-19. 1287 Tanda A, Huitzil-Melendez F. P-319 Delay in pancreatic cancer diagnosis and treatment: Call 1288 to action. Annals of Oncology. 2023;34:S127. 1289 20. Keane MG, Horsfall L, Rait G, Pereira SP. A case-control study comparing the 1290 incidence of early symptoms in pancreatic and biliary tract cancer. BMJ open. 1291 2014;4:е005720-е. 1292 Liao W, Clift AK, Patone M, Coupland C, González-Izquierdo A, Pereira SP, et al. 21. 1293 Identifying symptoms associated with diagnosis of pancreatic exocrine and neuroendocrine 1294 neoplasms: a nested case-control study of the UK primary care population. British Journal of 1295 General Practice. 2021;71:e836-e45. 1296 22. Schmidt-Hansen M, Berendse S, Hamilton W. Symptoms of Pancreatic Cancer in 1297 Primary Care. Pancreas. 2016;45:814-8. 1298 Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. The Lancet. 23. 1299 2020;395:2008-20. 1300 24. [Available from: https://www.nice.org.uk.

1301 25. Hippisley-Cox J, Coupland C. Development and validation of risk prediction 1302 algorithms to estimate future risk of common cancers in men and women: prospective 1303 cohort study. BMJ Open. 2015;5:e007825-e. 1304 26. Hamilton W. The CAPER studies: five case-control studies aimed at identifying and 1305 quantifying the risk of cancer in symptomatic primary care patients. British Journal of 1306 Cancer. 2009;101:S80-S6. 1307 27. Usher-Smith J, Emery J, Hamilton W, Griffin SJ, Walter FM. Risk prediction tools for 1308 cancer in primary care. British Journal of Cancer. 2015;113:1645-50. 28. 1309 Humphris JL, Chang DK, Johns AL, Scarlett CJ, Pajic M, Jones MD, et al. The prognostic 1310 and predictive value of serum CA19.9 in pancreatic cancer. Annals of Oncology. 1311 2012;23:1713-22. 1312 29. Luo G, Jin K, Deng S, Cheng H, Fan Z, Gong Y, et al. Roles of CA19-9 in pancreatic 1313 cancer: Biomarker, predictor and promoter. Biochimica et Biophysica Acta (BBA) - Reviews 1314 on Cancer. 2021;1875(2):188409. 1315 30. Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the 1316 diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based 1317 appraisal. J Gastrointest Oncol. 2012;3(2):105-19. 1318 Kim Y, Yeo I, Huh I, Kim J, Han D, Jang JY, et al. Development and Multiple Validation 31. 1319 of the Protein Multi-marker Panel for Diagnosis of Pancreatic Cancer. Clin Cancer Res. 1320 2021;27(8):2236-45. 1321 Potjer TP. Pancreatic cancer surveillance and its ongoing challenges: is it time to 32. 1322 refine our eligibility criteria? Gut. 2022;71:1047-9. 1323 Pereira S, Hippisley-Cox J, Timms J, Hsuan J, Fusai K, Williams N, et al. ADEPTS 33. 1324 (Accelerated Diagnosis of neuroEndocrine and Pancreatic TumourS) and EDRA (Early 1325 Diagnosis Research Alliance). Pancreatology. 2020;20(8):e14. 1326 34. Price S, Spencer A, Medina-Lara A, Hamilton W. Availability and use of cancer 1327 decision-support tools: a cross-sectional survey of UK primary care. Br J Gen Pract. 1328 2019;69(684):e437-e43. 1329 35. Menon U, Gentry-Maharaj A, Burnell M, Singh N, Ryan A, Karpinskyj C, et al. Ovarian 1330 cancer population screening and mortality after long-term follow-up in the UK Collaborative 1331 Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 1332 2021;397(10290):2182-93. 1333 Nené NR, Ney A, Nazarenko T, Blyuss O, Johnston HE, Whitwell HJ, et al. Serum 36. 1334 biomarker-based early detection of pancreatic ductal adenocarcinomas with ensemble 1335 learning. Communications Medicine. 2023;3:10-. 1336 37. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, et al. Sensitivity 1337 and specificity of multimodal and ultrasound screening for ovarian cancer, and stage 1338 distribution of detected cancers: results of the prevalence screen of the UK Collaborative 1339 Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009;10(4):327-40. 1340 Menon U, Gentry-Maharaj A, Ryan A, Sharma A, Burnell M, Hallett R, et al. 38. 1341 Recruitment to multicentre trials--lessons from UKCTOCS: descriptive study. Bmj. 1342 2008;337:a2079. 1343 39. O'Brien DP, Sandanayake NS, Jenkinson C, Gentry-Maharaj A, Apostolidou S, 1344 Fourkala EO, et al. Serum CA19-9 is significantly up-regulated up to 2 years prior to diagnosis 1345 with pancreatic cancer: implications for early disease detection. Clin Cancer Res. 1346 2015;21(3):622-31.

medRxiv preprint doi: https://doi.org/10.1101/2023.12.24.23300505; this version posted December 28, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 1347 40. Data normalization and standardization [Available from: 1348 https://www.olink.com/content/uploads/2021/09/olink-data-normalization-white-paper-1349 v2.0.pdf. 1350 41. Nené NR, Ney A, Nazarenko T, Blyuss O, Johnston HE, Whitwell HJ, et al. Early 1351 detection of pancreatic ductal adenocarcinomas with an ensemble learning model based on 1352 a panel of protein serum biomarkers. medRxiv. 2021:2021.12.02.21267187. 1353 Caruana R, Niculescu-Mizil A, Crew G, Ksikes A. Ensemble selection from libraries of 42. 1354 models. Proceedings of the twenty-first international conference on Machine learning; 1355 Banff, Alberta, Canada: Association for Computing Machinery; 2004. p. 18. 1356 43. Whalen S, Pandey G, editors. A Comparative Analysis of Ensemble Classifiers: Case 1357 Studies in Genomics. 2013 IEEE 13th International Conference on Data Mining; 2013 7-10 1358 Dec. 2013. 1359 44. Ambroise C, McLachlan GJ. Selection bias in gene extraction on the basis of 1360 microarray gene-expression data. Proc Natl Acad Sci U S A. 2002;99(10):6562-6. 1361 45. Whalen S, Schreiber J, Noble WS, Pollard KS. Navigating the pitfalls of applying 1362 machine learning in genomics. Nat Rev Genet. 2022;23(3):169-81. 1363 Teschendorff AE. Avoiding common pitfalls in machine learning omic data science. 46. 1364 Nat Mater. 2019;18(5):422-7. 1365 47. Julia H-C, Carol C. Development and validation of risk prediction algorithms to 1366 estimate future risk of common cancers in men and women: prospective cohort study. BMJ 1367 Open. 2015;5(3):e007825. 1368 48. Scholbeck CA, Molnar C, Heumann C, Bischl B, Casalicchio G, editors. Sampling, 1369 Intervention, Prediction, Aggregation: A Generalized Framework for Model-Agnostic 1370 Interpretations. Machine Learning and Knowledge Discovery in Databases; 2020 2020//; 1371 Cham: Springer International Publishing. 1372 49. James AD, Richardson DA, Oh IW, Sritangos P, Attard T, Barrett L, et al. Cutting off 1373 the fuel supply to calcium pumps in pancreatic cancer cells: role of pyruvate kinase-M2 1374 (PKM2). Br J Cancer. 2020;122(2):266-78. 1375 50. Matull WR, Andreola F, Loh A, Adiguzel Z, Deheragoda M, Qureshi U, et al. MUC4 1376 and MUC5AC are highly specific tumour-associated mucins in biliary tract cancer. Br J 1377 Cancer. 2008;98(10):1675-81. 1378 Cuenco J, Wehnert N, Blyuss O, Kazarian A, Whitwell HJ, Menon U, et al. 51. 1379 Identification of a serum biomarker panel for the differential diagnosis of 1380 cholangiocarcinoma and primary sclerosing cholangitis. Oncotarget. 2018;9(25):17430-42. 1381 52. Stecher C, Battin C, Leitner J, Zettl M, Grabmeier-Pfistershammer K, Höller C, et al. 1382 PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to 1383 Allogeneic Dendritic Cells. Frontiers in Immunology. 2017;8. 1384 Riquelme E, Zhang Y, Zhang L, Montiel M, Zoltan M, Dong W, et al. Tumor 53. 1385 Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. Cell.

1386 2019;178(4):795-806 e12. 1387 Peng H, James CA, Cullinan DR, Hogg GD, Mudd JL, Zuo C, et al. Neoadjuvant 54. 1388 FOLFIRINOX Therapy Is Associated with Increased Effector T Cells and Reduced Suppressor 1389 Cells in Patients with Pancreatic Cancer. Clinical Cancer Research. 2021;27(24):6761-71. 1390 Wang C, Li X, Zhang L, Chen Y, Dong R, Zhang J, et al. miR-194-5p down-regulates 55.

1391 tumor cell PD-L1 expression and promotes anti-tumor immunity in pancreatic cancer. Int 1392 Immunopharmacol. 2021;97:107822.

1393 56. QCancer<sup>®</sup>-2018 risk calculator for men: http://qcancer.org/male [

1394 QCancer<sup>®</sup>-2018 risk calculator for women: http://qcancer.org/female [ 57.

1395 58. Kane LE, Mellotte GS, Mylod E, O'Brien RM, O'Connell F, Buckley CE, et al. Diagnostic 1396 Accuracy of Blood-based Biomarkers for Pancreatic Cancer: A Systematic Review and Meta-

- 1397 analysis. Cancer Res Commun. 2022;2(10):1229-43.
- 1398 Sturm N, Ettrich TJ, Perkhofer L. The Impact of Biomarkers in Pancreatic Ductal 59. 1399 Adenocarcinoma on Diagnosis, Surveillance and Therapy. Cancers. 2022;14:217-.
- 1400 Azizian A, Ruhlmann F, Krause T, Bernhardt M, Jo P, Konig A, et al. CA19-9 for 60.

1401 detecting recurrence of pancreatic cancer. Sci Rep. 2020;10(1):1332.

- 1402 61. Sagi O, Rokach L. Ensemble learning: A survey. WIREs Data Mining and Knowledge 1403 Discovery. 2018;8(4):e1249.
- 1404 Benjamin JL, Maruan A-S, Amir A, Jennifer W, Sami L, Eric PX. Discriminative 62.
- 1405 Subtyping of Lung Cancers from Histopathology Images via Contextual Deep Learning. 1406 medRxiv. 2022:2020.06.25.20140053.
- 1407 63. Placido D, Yuan B, Hjaltelin JX, Zheng C, Haue AD, Chmura PJ, et al. A deep learning 1408 algorithm to predict risk of pancreatic cancer from disease trajectories. Nat Med.

1409 2023;29(5):1113-22.

- 1410 64. Whitwell HJ, Worthington J, Blyuss O, Gentry-Maharaj A, Ryan A, Gunu R, et al.
- 1411 Improved early detection of ovarian cancer using longitudinal multimarker models. British
- 1412 Journal of Cancer. 2020;122(6):847-56. 1413
- 1414